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ABSTRACT 
 
 
Objectives: 
 
 Simple, rapid, non hazardus, accurate, non expensive and 
precise spectrophotometric method was developed and 
optimized for the determination of acetylcysteine( antidote for 
paracetamol poisoning) and aminocaproic acid(antifibrinolytic 
drug) in their  pure forms and pharmaceutical formulations. The 
official methods for these drugs were non aqueous titration for 
acetylcysteine which is hazardous and non accurate or HPLC for 
aminocaproic acid which is expensive. The study included a 
color development for the assay of these drugs, investigation of 
the optimum reaction conditions for the developed color, and the 
validity of the proposed methods. 
The study also included the effect of possible interfering 
substances and traces of other amino acids. 
Methodology:  
Acetylcysteine 
The developed method was applied for analysis of this drug; it 
utilized 2, 6-dichloroquinone-4-chloroimide (DCQ) reagent 
which react with Acetylcysteine producing a more UV 
absorbing complex. The other part utilized ascorbic acid 
reaction with the primary aliphatic amine (aminocaproic acid). 
Results: 
The Acetylcysteine-DCQ complex gave linearity that obeyed 
Beerś law with correlation coefficient of 0.998 in the 
concentration range 10-50 µg/ml at 438 nm.  
Aminocaproic acid –ascorbic acid complex gave linearity at 530 
nm i.e. obeyed Beerś law with correlation coefficient of 0.999 in 
the concentration range 4-20 µg/ml. These methods were 
optimized and validated. The precision of the method was 
determined using  three different concentrations of NAC .The 
 XVI 
 
results showed a low (SD) varying from 3.055x10-3  to 1x10-3   
with relative standard deviation(RSD %) varying  from 2.47 to 
1.66 % for acetylcysteine concentrations in the range 6.19x10-5 
to 3.06x10-4  M. This reflected reproducibility of the method 
The validity of the method was tested by analyzing samples of 
acetylcysteine. 
Under the optimum experimental conditions employed, Beers 
law was found to be valid over the concentration range [6.1 x 
10-5 M – 3.05 x 10-4 M]. 
The molar absorptivity (ε) of the complex was 2130.96 L mole -
1 cm -1. 
Beerś law was obeyed for aminocaproic acid concentration 4 – 
20 µg/ml (3.049 x 10-5 M - 1.52 x 10-4 M). The molar 
absorptivity (ε) of the complex was 2492.6 L mole-1 cm-1. The 
high (ε) confirmed the sensitivity of the method. 
The accuracy of the procedure and freedom of interference by 
the injection excipients was confirmed by the obtained results 
for recovery testing of added amount of authentic ACA to the 
injection solution in the ratio of 1:1.The results showed good 
recovery for the injection (  =108.23±1.45, n = 3). This, together 
with the good reproducibility reflected the good accuracy and 
precision of the method.   
Conclusion: 
The developed methods were successfully applied in the 
quantitative assay of commercial capsules and injections, results 
of the analysis by the developed methods were found to be 
similar to those obtained by the official methods. 
The developed methods are simple, rapid and of high accuracy. 
They recommended for use in routine analysis.  
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  ﻃﺮوﺣﺔﻣﺴﺘﺨﻠﺺ اﻻ
 
  :اﻷهﺪاف 
ﻋﻘﺎﺭﻱ ﺍﻟﺴﺴﺘﻴل ﺴﻴﺴﺘﻴﻴﻥ ﺘﺭﻴﺎﻕ ﺍﻟﺠﺭﻋﺔ  ﻁﺭﻕ ﺘﺤﻠﻴل ﻁﻴﻔﻴﺔ ﻟﺘﺤﻠﻴل ﺍﺴﺘﺤﺩﺍﺙ
ﻓﻲ ﺼﻭﺭﻫﻤﺎ  ﺍﻟﺯﺍﺌﺩﺓ ﻤﻥ ﺍﻟﺒﺎﺭﺍﺴﻴﺘﺎﻤﻭل ﻭ ﺍﻻﻤﻴﻨﻭﻜﺎﺒﺭﻭﻴﻙ ﺍﺴﻴﺩ ﻤﻀﺎﺩ ﺘﺤﻠل ﺍﻟﺠﻠﻁﺔ
  .ﻓﻲ ﺍﻻﺸﻜﺎل ﺍﻟﺼﻴﺩﻻﻨﻴﺔ ﺍﻟﻤﺨﺘﻠﻔﺔﺍﻟﻨﻘﻴﺔ ﺍﻭ 
  .ﻠﻙ ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕﺜﻴﺭ ﺍﻟﻤﻭﺍﺩ ﺍﻟﻤﻀﺎﻓﺔ ﺍﻟﻤﺴﺘﺨﺩﻤﺔ ﻓﻲ ﺘﺭﻜﻴﺏ ﺘﺩﺭﺍﺴﺔ ﺘﺎ
  .ﻟﺫﻟﻙ ﻟﻤﺜﺎﻟﻴﺔﻥ ﺍﻟﻠﻭﻥ ﻭ ﺍﻟﻅﺭﻭﻑ ﺍﻟﻤﻌﻤﻠﻴﺔ ﺍﻴﺩﺭﺍﺴﺔ ﺘﻜﻭ
  .ﺩﺭﺍﺴﺔ ﺤﺴﺎﺴﻴﺔ ﺍﻟﻁﺭﻴﻘﺔ ﺍﻟﻤﺴﺘﺤﺩﺜﺔ
  :ﻣﻨﻬﺠﻴﺔ اﻟﺒﺤﺚ 
ﺍﻟﻜﻴﻥ ﺜﻨﺎﺌﻲ -6ﻭ2ﻤﻊ ﺍﻟﺴﺴﺘﻴل ﺴﺴﺘﻴﻴﻥ ﺍﻟﻁﺭﻴﻘﺔ ﺍﻟﻤﺴﺘﺤﺩﺜﺔ ﺘﻤﺕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺘﻔﺎﻋل 
 .ﻜﻠﻭﺭﻴﻤﺎﻴﺩ ﻟﻴﻌﻁﻲ ﻤﺭﻜﺏ ﺍﻜﺜﺭ ﺍﻤﺘﺼﺎﺼﺎ ﻟﻼﺸﻌﺔ ﻓﻭﻕ ﺍﻟﺒﻨﻔﺴﺠﻴﺔ-4- ﺍﻟﻜﻴﻨﻭﻥ 
ﺍﻟﺜﺎﻨﻲ ﺍﺴﺘﺨﺩﻡ ﺘﻔﺎﻋل ﺤﺎﻤﺽ ﺍﻻﺴﻜﻭﺭﺒﻴﻙ ﻤﻊ ﺍﻻﻤﻴﻨﺎﺕ ﺍﻟﻼﺤﻠﻘﻴﺔ ﺍﻻﻭﻟﻴﺔ ﺍﻟﺸﻕ 
ﺍﻟﻁﺭﻴﻘﺔ ﻋﻠﻲ ﺍﻟﻌﻼﻗﺔ ﺍﻟﺨﻁﻴﺔ ﺒﻴﻥ ﺘﺭﻜﻴﺯ ﺍﻋﺘﻤﺩﺕ . ﺍﻻﻤﻴﻨﻭﻜﺎﺒﺭﻭﻴﻙ ﺍﺴﻴﺩ  ﻤﺘﻤﺜﻠﺔ ﻓﻲ
  .ﺍﻟﻤﻭﺍﺩ ﺍﻟﻔﻌﺎﻟﺔ ﻭﺍﻻﻤﺘﺼﺎﺼﻴﺔ
  :اﻟﻨﺘﺎﺋﺞ
  ﺭﻕ ﺍﻟﻤﺴﺘﺤﺩﺜﺔ ﻟﻜل ﺍﻟﻤﺴﺘﺤﻀﺭﺍﺕ ﻋﻼﻗﺔ ﺨﻁﻴﺔ ﻗﻭﻴﺔﺍﻋﻁﺕ ﺍﻟﻁ
ﻜﻠﻭﺭﻴﻤﺎﻴﺩ ﻋﻨﺩ ﻁﻭل -4-ﺍﻟﻜﻴﻥ ﺜﻨﺎﺌﻲ ﺍﻟﻜﻴﻨﻭﻥ - 6ﻭ2ﺍل ﻭ ﺍﻟﺴﺴﺘﻴل ﺴﺴﺘﻴﻴﻥ ﻤﻌﻘﺩ    
ﺍﻋﻁﻲ ﻋﻼﻗﺔ ﺨﻁﻴﺔ ﻭ ﺤﻘﻕ ﻗﺎﻨﻭﻥ ﺒﻴﺭ ﻭ ﻭﺠﺩ ﻤﻌﺎﻤل ﻨﺎﻨﻭﻤﺘﺭ  834ﺍﻟﻤﻭﺠﺔ 
 05- 01ﻭ ﺍﺜﺒﺘﺕ ﺍﻟﻨﺘﺎﺌﺞ ﻭﺠﻭﺩ ﺘﻨﺎﺴﺏ ﻁﺭﺩﻱ ﻓﻲ ﺍﻟﻤﺩﻱ ( 899.0)ﺍﻻﺭﺘﺒﺎﻁ 
     ﻤل/ﻤﺎﻴﻜﺭﻭﺠﺭﺍﻡ
ﻨﻭﻤﺘﺭ ﻨﺎ 035ﻤﻌﻘﺩ ﺍﻻﻤﻴﻨﻭﻜﺎﺒﺭﻭﻴﻙ ﺍﺴﻴﺩ ﻤﻊ ﺍﻻﺴﻜﻭﺭﺒﻙ ﺍﺴﻴﺩ ﻋﻨﺩ ﻁﻭل ﺍﻟﻤﻭﺠﺔ 
ﻭ ﺍﺜﺒﺘﺕ ( 999.0)ﺍﻋﻁﻲ ﻋﻼﻗﺔ ﺨﻁﻴﺔ ﻭ ﺤﻘﻕ ﻗﺎﻨﻭﻥ ﺒﻴﺭ ﻭ ﻭﺠﺩ ﻤﻌﺎﻤل ﺍﻻﺭﺘﺒﺎﻁ 
   ﻤل/ﻤﺎﻴﻜﺭﻭﺠﺭﺍﻡ 02-4ﺍﻟﻨﺘﺎﺌﺞ ﻭﺠﻭﺩ ﺘﻨﺎﺴﺏ ﻁﺭﺩﻱ ﻓﻲ ﺍﻟﻤﺩﻱ 
ﻭ  ﻓﻲ ﻗﻴﺎﺱ ﺠﺭﻋﺎﺕ ﺍﻻﺩﻭﻴﺔ ﺍﻟﻤﺸﺎﺭ ﺍﻟﻴﻬﺎ ﺼﻼﺤﻴﺘﻬﺎ ﺜﺒﺘﺕﺍﺍﻟﻁﺭﻕ ﺍﻟﻤﺴﺘﺤﺩﺜﺔ  
  .ﺍﻟﻅﺭﻭﻑ ﺍﻟﻘﺼﻭﻯ ﻟﻬﺎ
  IIIVX
 
ﻭ  ﻴل ﺴﺴﺘﻴﻴﻥﺎﺴﺘﺘﺭﺍﻜﻴﺯ ﻤﺨﺘﻠﻔﺔ ﻟﻼ ﺩﻗﺔ ﺍﻟﻁﺭﻴﻘﺔ ﺍﻻﻭﻟﻲ ﻋﻠﻲ ﺜﻼﺜﺔ ﺍﺨﺘﺒﺎﺭﺘﻡ 
 ﺍﻅﻬﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻨﺤﺭﺍﻑ ﻤﻌﻴﺎﺭﻱ ﻤﻨﺨﻔﺽ  ﻤﻊ ﺩﺭﺠﺔ ﺍﻨﺤﺭﺍﻑ ﻗﻴﺎﺴﻲ  ﻤﻥ 
  %( .  66.1ﺇﻟﻰ %   74.2 ﻤﻥ)  3- 01×  1ﺇﻟﻰ    3- 01×  550.3ﻤﻥ 
ﺘﺤﺕ ﺍﻟﻅﺭﻭﻑ ﺍﻟﻤﻌﻠﻤﻴﺔ ﺍﻟﻤﺜﻠﻰ ﻭﺠﺩ ﺃﻥ ﻗﺎﻨﻭﻥ ﺒﻴﻴﺭ ﻴﻁﺒﻕ ﻋﻠﻰ ﻤﺩﻯ ﺍﻟﺘﺭﻜﻴﺯ    
ﻤﻭل /ﻟﺘﺭ 0312ﺒﺎﻤﺘﺼﺎﺼﻴﺔ ﻤﻭﻻﺭﻴﺔ   4-01×  50.3 ﺇﻟﻰ 5-01×  1.6ﺍﻟﻤﻭﻻﺭﻱ 
  .ﺴﻨﺘﻤﺘﺭ
  اﻻﻣﻴﻨﻮآﺒﺮوﻳﻚ اﺳﻴﺪ
ﺍﻟﻲ  4ﺘﺤﺕ ﺍﻟﻅﺭﻭﻑ ﺍﻟﻤﻌﻠﻤﻴﺔ ﺍﻟﻤﺜﻠﻰ ﻭﺠﺩ ﺃﻥ ﻗﺎﻨﻭﻥ ﺒﻴﻴﺭ ﻴﻁﺒﻕ ﻋﻠﻰ ﻤﺩﻯ ﺍﻟﺘﺭﻜﻴﺯ 
ﻫﺫﻩ ﺍﻟﻘﻴﻤﺔ .ﻤﻭل ﺴﻨﺘﻤﺘﺭ/ﻟﺘﺭ 6.2942ﻤل ﺒﺎﻤﺘﺼﺎﺼﻴﺔ ﻤﻭﻻﺭﻴﺔ  /ﻤﺎﻴﻜﺭﻭﺠﺭﺍﻡ 02
  .ﺍﻟﻌﺎﻟﻴﺔ ﺘﺅﻜﺩ ﺤﺴﺎﺴﻴﺔ ﺍﻟﻁﺭﻴﻘﺔ
 ﺘﺎﺜﺭﻫﺎ ﺒﺎﻟﻤﻭﺍﺩ ﺍﻟﻤﻀﺎﻓﺔ ﻟﻠﺤﻘﻥ ﺒﺎﻀﺎﻓﺔ ﻋﻴﻨﺎﺕ ﺍﺼﻴﻠﺔ ﻤﻥﺘﺎﻜﺩ ﺩﻗﺔ ﺍﻟﻁﺭﻴﻘﺔ ﻭ ﻋﺩﻡ 
  ﺍﻟﺘﺭﺍﺠﻊ ﺠﻴﺩ  ﻟﻠﺤﻘﻥ ﻭ ﻭﺠﺩ ﺍﻥ ﺍﻻﻤﻴﻨﻭﻜﺒﺭﻭﻴﻙ ﺍﺴﻴﺩ
   )3 = n ,54.1±32.801= (
  اﻟﺨﻼﺻﺔ 
ﺨﻠﺼﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻲ ﺍﻥ ﻨﺘﺎﺌﺞ ﺍﻟﺘﺤﺎﻟﻴل ﺒﺎﻟﻁﺭﻕ ﺍﻟﻤﺴﺘﺤﺩﺜﺔ ﻟﻼﺩﻭﻴﺔ ﻤﻭﻀﻭﻉ ﺍﻟﺒﺤﺙ 
ﺍﻟﻤﺘﺤﺼل ﻋﻠﻴﻬﺎ ﺒﺎﻟﻁﺭﻕ ﻙ ﻤﻁﺎﺒﻘﺔ ﻟﺩﺭﺠﺔ ﻜﺒﻴﺭﺓ ﻟﺘﻠﻓﻲ ﺍﻻﺸﻜﺎل ﺍﻟﺼﻴﺩﻻﻨﻴﺔ ﺍﻟﻤﺨﺘﻠﻔﺔ 
ﻓﺎﻥ ﺍﻟﻁﺭﻕ ﺍﻟﻤﺴﺘﺤﺩﺜﺔ ﺘﻌﺘﺒﺭ ﺍﻻﻓﻀل ﻻﻨﻬﺎ ﻏﻴﺭ  ﻬﺎ ﻟﺫﻟﻙﺍﻟﺩﺴﺘﻭﺭﻴﺔ ﺍﻟﻤﻌﺘﻤﺩﺓ ﻋﻠﻴ
ﻓﻲ ﻤﻌﺎﻤل  ﺭﻭﺘﻴﻨﻲﻟﻤﻜﻠﻔﺔ ﻭ ﺴﺭﻴﻌﺔ ﻭ ﺒﺴﻴﻁﺔ ﻤﻤﺎ ﻴﻤﻜﻥ ﻤﻥ ﺍﺴﺘﺨﺩﺍﻤﻬﺎ ﻓﻲ ﺍﻟﺘﺤﻠﻴل ﺍ
  .ﻀﺒﻁ ﺍﻟﺠﻭﺩﺓ
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LIST OF SYMBOLS AND ABBREVIATIONS 
 
NAC N_acetylcysteine 
ACA Aminocaproic acid 
ABS Absorbance 
DCQ 2, 6_dichloroquinone _4_chloroimide 
SD Standard 
RS Reference Standard 
 Ac* Reactive electrophilic compound  
MFO Mixed function oxidases  
GSH Glutathione 
HIV Human immunodeficiency virus 
AIDs Acquired immunodeficiency disease  
LP (a) lipoprotein A 
LDL Low density lipoprotein 
BNF Britich national formulary 
USP united States pharmacopeia 
BP Britich pharmacopeia 
DMSO Dimethylsulfoxide  
Mixture water  50:50 absolute ethanol and distilled  
M molar concentration 
VS volumetric standard  
mg Milligram 
h Hour 
min Minute  
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1. INTRODUCTION 
 
1.1 Acetylcysteine 
1.1.1 Definition: 
Acetylcysteine ; N- acetyl – L- cysteine (C5 H9 NO3 S), L- alpha – 
acetamido – beta – mercaptopropionic acid [L-α_ a cetamido - β 
mercaptoproionic acid, N – acetyl – 3 – mercaptoalaline] 
(NAC).The merck index (8th edition ).  
Is the antidote of acetaminophen intoxications (Text book of 
pharmacology; 1992). 
 
 
Figure (1): Acetylcysteine structure  
(Reproduced from USP/NF, 2008). 
 
 
 
 
 
 
 2 
It's the metabolite and acetylated form of the sulfur containing 
amino acid L.cysteine (LE magazine, 2004).  
Unlike cysteine it's an endogenous substance produced within the 
human body. NAC is sometimes considered as a dietary 
supplement. Sulfur- containing nutrients play several critical roles 
in the body including detoxification, protecting cells and cellular 
components against oxidative stress. NAC contains a sulfhydral 
group, sulfhydral compounds are excellent radiation protectors 
and are also free – radical scavengers, peroxide decomposers, 
catalysts of sulfhydral – disulfide exchange and possibly can 
implement repair of damaged sites(Richard A.passwater NAC an 
old nutrients attracts new researchers ) .  
1.1.2 Physical Properties:  
Acetylcysteine (Mwt 163.19) is a white solid (crystalline solid). 
M.P: 109 °c (228.2 °f) (Science lab.com,material safety data sheet 
NAC,2005) 
1.1.3 Pharmacology:  
1.1.3.1 Mechanism of Action:  
Analgesic drugs are all likely to be taken in overdoes. Of these 
drugs is acetaminophen (ABC of poisoning drugs; 1985). 
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Figure (2) Acetaminophen structure (Reproduced from Text 
book of pharmacology; 1992). 
 
This drug when ingested is rapidly and completely absorbed, 
reaching a peak plasma concentration in 30 – 60 min with a 
plasma t½ of 2 hours, slightly bound to plasma protein, 
extensively metabolized by hepatic microsomal enzymes to 
glucouronides (60%) and sulfates (35%) which are almost entirely 
excreted by the kidney within 24 hours. An important 
_quantatively minor_ part (4%) is metabolized by the p – 450 
MFO system to a reactive metabolite N-acetylbenzoquinone (the 
N- hydroxylated metabolite) (Text book of pharmacology; 1992), 
which subsequently dehydrates to a chemically reactive 
acetimidoquinone before binding covalently with cellular 
macromolecules lead to hepatic necrosis} is detoxified by 
glutathione to cysteine and mercapturic acid metabolites. 
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Figure (3) N- acetylbenzoiminoquinone  
(N-hydroxylated product). 
A key role of glutathione in hepatocytes is to protect against 
structural and functional damage of macromolecules resulting 
from attack by reactive electrophilic substances generated in the 
course of metabolism. Glutathione, being strongly nucleophilic, 
mops up the electrophilic metabolites. Depletion of glutathione 
increasing the toxicity of substances yielding electrophilic 
metabolites, whereas an increase in the glutathione level 
decreases their toxicity (Text book of pharmacology; 1968) 
 Types of substrates undergo glutathione conjugation are: 
Epoxides, areneoxide, nitro groups and hydroxylamine's.  
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Figure (4) Metabolism of phenancetin and paracetamol 
(Reproduced from Pharmacology; 4th edition Churchill living 
stone; 1999). 
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Figure (5) formation of glutathione conjugate and then 
mercaptouric acid conjugate from an epoxide. Ac* in this case 
(Text book of pharmacology 2nd edition; 1968). 
    
*glutathione (HS-G)] γ -glutamyl-cysteinyl-glycine ] cysteine 
here is the amino acid source  of  SH group of  GSH molecule  
** By enzyme: peptidases these enzymes are most active in 
kidney but are also present in liver. 
*** Reaction through SH of cysteine moiety. 
**** coA acetylation by enzyme in liver.  
** 
*** 
* 
**** 
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 At higher dosages more acetaminophen is converted to the 
AC* because the conjugation pathways become saturated. It's 
important to note that paracetamol toxicity occurs when taken for 
prolonged periods (daily or weekly for years) or in massive doses. 
As glutathione stores are depleted, the reactive intermediate binds 
to other cellular proteins and produces hepatic necrosis and renal 
dysfunction by the same etiology (Reproduced from text book of 
pharmacology; 1992). Acetaminophen is quiet safe in therapeutic 
doses (1.2 gram/day for an adult). With massive doses (10 – 15 
gram), Hepatic toxicity may occur which is potentially lethal in 
doses of 20 – 25 g. It's important to note that in many cases there 
are no symptoms for acetaminophen poisonings which is divided 
into four stages: 
The first (12 – 24 hrs post exposure) is characterized by anorexia, 
nausea, vomiting and diaphoresis. 
The second (1 – 2 days) is associated with clinical improvement; 
the prothrombin time and plasma levels of hepatic transaminases 
and bilirubin begin to increase. 
The third stage (3 – 4 day) hepatotoxitity manifested by 
centrilobular necrosis, usually reaches its peak.  
The fourth (5 – 7 days) mildly poisoned individuals enter this 
stage and recover (ABC of poisoning drugs; 1985). 
Sever intoxications lead to hepatic encephalopathy that progress 
from confusion to coma to death, some patient also exhibit acute 
renal failure (Text book of pharmacology; 1992).  
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Figure (6) paracetamol poisoning symptoms (Reproduced 
from ABC of poisoning drugs; 1985). 
   
N – Acetyl cysteine is the antidote for acetaminophen poisoning. 
This drugs act by both decreasing the conversion of 
acetaminophen to its toxic product (modulates cyp _450 enzyme 
responsible for producing the AC* of acetaminophen) and by 
complexing with toxic product. 
Liver microsomal cyp_450 enzyme system has an absolute 
requirement for NADPH and molecular oxygen. 
ArNH2 + NADPH + O2 P450-MO    ArNHOH 
N- Hydroxylated product of acetaminophen 
Whereas:  
GSSG+NADPH+H ---------? 2GSH + NADP (Harperś 
biochemistry; 2000). 
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GSSG consumer of NADOPH that P450 requires. 
The oxide mechanism for the florin-containing mono-oxygenases  
appears to involve the formation of an NADPH .O2. flavin 
intermediate, which can transfer an oxygen atom to the 
heteroatom (e.g. N or S) yielding the hetero atom oxide, 
selectivity of substrate heteroatom oxidation appears to depend 
upon the nucleophilicity of the hetero atom. 
As if acetylcysteine (SH groups) and acetaminophen (NH) groups 
competes in cyp450 
 
  
 
 
 
 
 
 
 
 
 
 
Figure (7) Comparison between NAC and paracetamol. 
Predominates NAC 
because N is more 
nucleophilic than S  
CYP 450 
H 
N C 
O 
CH3
OH 
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Acetylcysteine is rapidly metabolized to intracellular glutathione, 
while purified GSH available as dietary supplement has low 
absorption thus NAC is thought to be a better method of boosting 
cellular glutathione levels (Advanced health and life extension 
NAC). Acetylcysteine acts as immediate precursor for 
glutathione, [a tripeptide antioxidant made up of the three amino 
acids cysteine, glycine and glutamate].  Glutamate and glycine are 
available in diet, cysteine availability is the rate limiting step for 
the synthesis of glutathione within the cell, cysteine is not itself 
nutritionally essential is formed from methionine (essential amino 
acid) and serine (non essential amino acid), cyteine as such  is 
potentially toxic and is spontaneously catbolised in the GIT and 
blood plasma (Cysteine; Wikipedia the free encyclopedia). Thus 
the free amino acid cysteine doesn't represent an ideal delivery 
system to the cell this is why NAC is the suitable precursor for 
cysteine and glutathione. Furthermore, NAC is well absorbed and 
readily crosses cell membranes, rapidly metabolized and only10%  
of the amount consumed stays in the blood for an appreciable 
time, much of NAC is rapidly consumed in producing 
intracellularglutathione(RichardApasswaterph.D.WWW.healthy.n
et/asp/templates /article .asp:N_acetylcysteine (NAC): an old 
nutrient that attracts new research ;) 
 While glycine and L-glutamic acid are plentiful in our diets, the 
amount of glutathione our bodies can produce is limited by their 
store of cysteine, which sometimes is in short supply, 
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supplementation with NAC thus helps the body produce 
glutathione at more beneficial level, NAC can be effective in 
treating liver failure from causes other than acetaminophen 
poisoning including hepatitis and other drug toxicity 
(www.eVitamins, what is NAC; 2009). 
In kidneys, NAC prevent kidney damage caused by injections of 
Iopromide, a contrast medium used in people scheduled to 
undergo computerized tomography (CT) imaging.  Oral 
supplementation with NAC has been used successfully in two 
cases to treat a rare syndrome that complicates kidney dialysis.  
This condition, known as pseudoporphyria, has no other known 
treatment.  Controlled clinical trials are needed to confirm these 
preliminary observations (www.eVitamins;What is NAC; 2009).  
NAC has demonstrated benefits for people with pre-existing 
kidney damage who are undergoing coronary angiogram tests and 
are at risk for further kidney damage from the injected dye used to 
visualize the coronary arteries(LE magazine;2004). In a double 
blind study, oral administration of NAC reduced by 86% the 
incidence of kidney damage in people undergoing this procedure.  
The amount of NAC used in that study was 400 mg twice a day, 
on the day before and the day of the procedure.  Other studies 
have shown that NAC is protective only when a low dose of dye 
is used (www.eVitamins;What is NAC; 2009) Formation and 
recurrence of kidney stones may also be circumvented by NAC 
supplementation. 
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NAC doesn't seem to raise tissue or blood levels of glutathione 
above the desired ranges. Thus the nutrient role of NAC is to help 
maintain healthy levels of intracellular glutathinone, especially 
whenever a condition has limited glutathione production 
(Richard.A. passwater ph.D.WWW.healthy.net/asp/templates 
/article .asp:N_acetylcysteine (NAC): an old nutrient that attracts 
new research ;) .   
NAC, glutathione and cysteine protect against toxins, is 
particularly effective as it detoxifies several toxic agents 
including heavy metals as zinc, copper, arsenic, lead , cadmium  
and mercury (mercurials are eliminated in the urine in complexes 
with the monothiol radicals of cysteine or NAC ; Text book of 
pharmacology ;1968). 
Drugs including:  Tylenol, herbicides as (paraquat), 
environmental pollutants: acrolein (found in cigarette smoke and 
auto exhaust, ccl 4, chloroform, co and urethane.  Side effects of   
anticancer drugs as cyclophosphamide, ifosphamide doxyrubicin 
and adriamycin. 
Side effects of  anaesthetic as (halothane) valproic acid and 
alcohol. Microorganisms including aflatoxin and Escherichia Coli 
and some viruses.  NAC, GSH and cysteine either directly react 
with many poison, or act as second line of body defense against 
toxins in liver and various individual cells (Richard.A. 
passwaterph.D.WWW.healthy.net/asp/templates/article.asp:N_ 
acetylcysteine (NAC): an old nutrient that attracts new research;), 
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and help remove them  {NAC increase  the excretion of zinc and 
other essential minerals when taken over an extended period of 
time, it's therefore necessary to supplement zinc, copper and other 
trace minerals  when taking   NAC for extended periods as NAC 
increases urinary zinc excretion  } , {sulfahydral compounds and 
vitamin E  also increase the body tolerance to Selenium (Richard. 
A. passwaterph. D.WWW. healthy. net/asp/templates /article .asp: 
N_acetylcysteine (NAC): an old nutrient that attracts new 
research ;):GSH removes (H2O2) from the erythrocyte. 
 In a reaction by enzyme glutathione peroxidase , which contains 
selenium as essential component of the enzyme)toxins indirectly 
via the enzyme P450 system.  Giving rise to GSH, make NAC has 
a second role in detoxification as GSH conjugates phase II 
detoxification with most foreign compounds, then these 
compounds pass harmlessly out of the body through the biliary 
system ( Richard A pass water pH.D.WWW.healthy.net/asp/N 
acetylcysteine (NAC) an old nutrient that attract new research) 
  The same mechanism of producing GSH is the reason why NAC 
act as antioxidant.  GSH is often considered the body's most 
important antioxidant because of its location within every cell.  
Reactive oxygen inter mediates commonly called "free radicals" 
which are the toxic waste products of normal cellular metabolism 
, they interrupt the cellular regenerative process, eventually 
damaging cells, they also mediate mechanisms that contribute in 
the development of several neurodegenerative diseases, even 
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suspected as a major factor in the body's aging process (LE 
magazine ,2004). 
Oxidative stress can result in serious cell damage if the stress is 
massive or prolonged .In a normal cell, there is an appropriate 
pro_oxidants:antiantioxidant balance. 
Antioxidant scavenges free radicals, effectively neutralizing them 
and contributing to more efficient liver function.  They also 
improve food quality and stability by inhibiting the free radical 
oxidation of food during its processing and storage.  NAC is a 
vital antioxidant whose effects include the scavenging of potent 
hydroxyl radicals and diminished production of hydrogen 
peroxide (H2O2) (LE magazine 2004). 
Since NAC is a powerful antioxidant nutrient, it has been of 
special interest to athletes for sometimes as heavy exercise 
increases oxidative   damage in the body [Body builders whose 
intense training usually causes temporary lower levels of GSH 
and NAC is used to replenish GSH]. Even the thiol metabolites of 
NAC are khown as good antioxidants.  NAC may also protect 
lung tissue through its antioxidant activity (Richard .A. pass 
water; NAC: an old nutrient attracts new research; 2008). 
Intracellular glutathione levels affect the ability of lung 
phagocytes to do other job properly.  Normal glutathione levels 
also show promise in treatment of several lung disorders. 
NAC is a mucolytic "mucous dissolving" agent used to reduce the 
viscosity of bronchial mucus.  It's often used as a cough medicine 
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as it breaks up the disulfide bonds into 2 sulfyhydral bonds and 
cleaving the mucoproteins into smaller molecules; the resultant 
change in molecular shape is considered to enhance the flow 
prosperities of the mucous. 
Sulfhydral groups are thought to reduce disulphide bonds in 
mucoproteins this action  reduces the chain length of 
mucoproteins, & thin the mucous thus liquefies it, making it 
easier to be coughed up or removed by suction.  This is of benefit 
for patients suffering from chronic respiratory conditions e.g. 
chronic cystic fibrosis, asthma, sinusitis pneumonia and chronic 
obstructive pulmonary disease. 
NAC supplements improved symptoms and prevent recurrent in 
people with chronic bronchitis (Richard .A.passwater, NAC an 
old nutrient attract new research, Advanced health and life 
extension). NAC can also be used to lessen the symptoms and 
duration of the flu and the common cold:  NAC at a dosage of 
1200 mg/day helps to prevent influenza infection, reduces the 
symptoms of existing influenza and reduces the duration of 
influenza infections (Advanced health and life extension). 
NAC's action as antioxidant and a glutathione precursor may also 
contribute to a protective effect against cancer.  It also reduces the 
toxic effects of some chemotherapeutic agents such as cisplastin 
and oxazophosporine-based agents (Richard.A.pass water NAC 
an old nutrient attract new research).  NAC  has been shown to 
reduce the proliferation of certain cells living the colon and may 
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reduce the risk of colon cancer in people with recurrent polyps in 
the colon (Advanced health and life extension ).  Aero digestive 
tract cancer risk observed in smokers and drinkers may be the 
result of the increased acetaldehyde exposure.  Acetaldehyde was 
significantly decreased by a buccal L-cysteine releasing tablet.  
Also smoking derived acetaldehyde could be totally removed by 
using a tablet containing L-cysteine (Ville salaspuro doctoral 
thesis; 2006). In cigarette additives cysteine could offer two 
benefits:  acting as an expectorant, since smoking increase mucus 
production in the hung; and increasing the beneficial antioxidant 
GSH which is diminished in smokers (LE magazine; 2004).  
Evidence from invitro and in vivo studies suggests that NAC is a 
promising inhibitor of tumorigenesis, it also reduces the 
carcinogen induced DNA adduction (Chemopreventive efficacy 
of arylalkyl isothiocyanate and NAC for lung tumerogenesis in 
fischer rats ;1995). 
NAC affects immunity via its role in intracellular glutathione 
production; this role becomes critical when normal GSH 
production pathways are impaired, as for example by HIV.  There 
is some evidence that reduced intracellular GSH is the direct and 
early consequence of retroviral infection.  NAC readily crosses 
cell membrane, even in HIV-infected cells, whereas glutathione 
doesn't enter into HIV-infected cells in adequate amounts.  NAC 
doesn't seem to raise tissue or blood levels of GSH above the 
desired ranges.  Thus, the nutrient role of NAC is to help maintain 
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healthy levels of intracellular GSH (Richard.A.passwater NAC an 
old nutrient attract new research). 
Intracellular GSH has a powerful influence on how well T- and 
B-lymphocytes function; GSH availability affects the production 
of phagocytes, It also aid in the transport of nutrients to 
lymphocytes and phagocytes, it also protect cell membranes.  
Free radicals can impair the immune system and NAC can protect 
against free radicals thus enhances the immune system.  NAC is 
regarded as a selective immune system enhancer. 
NAC has been shown to block the AIDs virus (HIV) production 
in vitro, apparently by GSH levels in HIV-infected cells.  Vitamin 
C and NAC had complementary actions to slow the replication of 
the AIDS virus.  NAC is investigated as a supplement treatment 
for HIV patients. 
A growing area of interest is that research has pinpointed a 
specific lipoprotein called Lp(a) as one of the two most reliable 
indicators of heart disease risk (Lpa and vitamin E).  Lp(a) is a 
much more reliable indicator than blood cholesterol level, LDL, 
HDL or their ratios to each other. 
Diets and drugs designed to lower blood cholesterol levels don't 
lowerLp(a) levels.  Lp(a) consists of a LDL particle attached to 
the large glycoprotein apo(a) by one or more disulfide bonds.  
NAC breaks up the disulfide bonds by converting each disulfide 
groups into two suflhydryl groups in two separate compounds.  
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Recent research has found that NAC is the most effective nutrient 
known to lower Lp(a) by almost 70%. 
NAC also inhibit heart damage by preventing LDL from being 
oxidized and by destroying free radicals produced after an 
infarction. 
NAC has been used in connection with angina pectoris, heart 
attack (I.V immediately following myocardial infraction).  It has 
also been used in connection with gastritis. 
There have been several case reports of oral NAC producing 
dramatic improvements in unvericht-lund borg disease, an 
inherited degenerative disorder involving seizures and progressive 
disability.  One study used 3 grams of NAC (per) day.  More 
recently, patients with other neurodegenerative conditions 
including amyotrophic lateral sclerosis, multiple sclerosis, 
diabetic neuropathy, and Alzheimer's disease have been treated 
with NAC.  NAC may also be useful in the treatment of cocaine 
addiction. 
1.1.3.2 Pharmacological actions: 
NAC supplementation counteracts acetaminophen intoxication; 
NAC boost GSH levels which are depleted by the active 
metabolite of acetaminophen (N-hydrocxylated-acetyl benzo 
imino quinone). 
 Many of the pharmacological actions of NAC are linked to the 
fact that it's the immediate precursor of GSH.  Thus any condition 
GSH levels, drug toxicities other than acetaminophen, hepatitis.  
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HIV patients whose GSH levels are diminished get benefit from 
NAC. 
NAC readily crosses cell membranes, even in HIV infected cells, 
whereas GSH doesn't enters into HIV-infected cells in adequate 
amounts, also NAC can protect against free radicals which if left 
unchecked can impair the immune system, by this way NAC 
enhances the immune system NAC ability to quench free radicals 
(which are the toxic waste products of normal cellular 
metabolism) makes it a powerful antioxidants. 
NAC is mucolytic, since it breaks up the disulfide bonds in 
mucoproteins into two sulfhydral groups i.e. cleaning 
mucoproteins into smaller molecules i.e. reduces the chain length 
of mucoproteins it's the resultant change in molecular shape is 
considered to enhance the flow prosperities of the mucus i.e. this 
mucus easier to be coughed up.  This action of NAC makes it of 
beneficiary for many common lung disorders. 
NAC recently was shown to reduce the proliferation of certain 
cells living the colon, and it may reduce the risk of colon cancer 
in people with recurrent polyps in the colon. 
NAC increases the urinary excretion of zinc and other essential 
minerals when taken over extended periods of time.  It's therefore, 
necessary to supplement zinc, copper and other trace minerals 
when taking NAC for extended periods of time. 
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NAC has no demonstrated selective or stimulant effects, and 
tolerance is excellent for the vast majority of people who takes it 
regularly. 
When taking NAC it's recommended that two to three times as 
much vitamin C is taken at the same time. The vitamin C helps 
keep the GSH that is produced from the cysteine in its reduced 
form so that it can continue acting as an antioxidant. 
NAC is well absorbed,rapidly metabolized, and only about 10% 
of the amount consumed stays in the blood for an appreciable 
time.  Much of NAC is very rapidly consumed in producing 
intracellular GSH.  It readily crosses cell membranes even in 
HIV-infected cells. 
 
1.1.3.3 Indications of NAC: 
 NAC is indicated as antidote for paracetamol intoxication 
Cyteamine may be used, but NAC is the safer of the two. NAC 
can be effective in treating liver failure from causes other than 
acetaminophen disease. 
NAC is indicated in obstruction pulmonary bronchitis and chronic 
as mucolytic agent, criteria very important for many common 
lung disorders (NAC used in some inhaled products USP 31, 
2008. 
NAC in eye preparations indicated to treat tear deficiency (BNF 
52, Sep 2006). 
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1.1.3.4 Side effects of NAC: 
NAC has no demonstrated sedative or stimulant effects, and 
tolerance is excellent for the vast majority of people who take it 
regularly. 
NAC in normal food supplementation ranges is without known 
toxicity.  Daily levels of 1000 mgs of NAC per kg in rats for 
several months didn't produce adverse effects in behavior, weight 
gain, hematology, liver function and kidney function (i.e. 
equivalent to 60 g to NAC/day for a 132 pound person, 80 g/day 
for 176 pound person or 100 g day for a 220 pound person).  
Individual reactions may vary and any one experiencing adverse 
symptoms while taking NAC should discontinue it. 
Larger quantities used for treating acetaminophen overdose have 
produced adverse reactions as nausea; vomiting and other 
gastrointestinal symptoms tinnitus (BNF 22, September 1991) had 
also been reported.  One study reported that 19% of people taking 
NAC orally experienced nausea, vomiting, headache, dry mouth, 
dizziness, or abdominal pain.  These symptoms however, have not 
been consistently reported by other researchers. 
Allergic reactions, urticaria, anaphylaxis have been reported. 
Rash, with or without mild fever, has been reported on rare 
occasions with very large quantities.  Iatrogenic over doses have 
occurred (ABC of poisoning drugs; 1985) intravenous 
administration of more than 150 mg of NAC per kg of body 
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weight within a 15 minute period may produce toxic or other 
undesirable effects. 
Hypersensitivity like reactions when NAC is used as infusion, can 
be managed by reducing infusion rate or suspending until reaction 
settled, Rash managed by giving nebulised short-acting beta 
agonist. 
As an aerosol NAC may intake the airway in sensitive 
individuals. 
When administered via nebulizer, adverse effects can include 
stomatitis, nausea and nasal irritation. Intravenous administration 
could also produce edema and a rapid heard beat. 
Although a great deal of research has shown that NAC has 
antioxidant activity, one small study found that daily amounts of 
1.2 g or more could lead to increased oxidative stress. 
Extremely large amounts of cysteine, the amino acids from which 
NAC is derived, may be toxic to nerve cells in rats. 
NAC may increase urinary zinc excretion.  Therefore, 
supplemental zinc and copper should be added when 
supplementing with NAC extended periods. 
The mouse LD50 of oral NAC is reported to be about 8000 mg of 
NAC kg in the mouse, and 5050 mg, kg in the rat. 
NAC  is very hazardous in case of skin contact (irritant, 
permeator), ingestion, or inhalation. 
1.1.3.5 NAC dosage forms: 
Aerosol, nebulizer, injection, tablets or capsules, I.V infusion 
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NAC is available as: 
Injections:  as 10 ml ampoules containing 29 (200 mg/ml). 
Eye drops:  acetyl cysteine 5%, hypomellose 0.35% (BNF 52, 
Sep. 2006) Parvolex®. 
Solution:  10 or 20% NAC as nebulizer spray for inhalation, oral 
nebulization route. 
Acetylcysteine and isopretenol hydrochloride 
Inhalation solution present in single-dose or multiple-dose 
containers, (USP 31, 2008). 
Solution:  Acetylcysteine in water. 
Capsules:  NAC vegetable capsules, 600 mg by Solgar. 
Granules: NAC 200 mg/sachet 
1.1.3.6 Dosage of NAC: 
Antidote for paracetamol overdose: 
Initial loading dose of 140 mg/kg followed by 70 mg/kg every 
hour for 72 hours. 
Orally by nasogastric tube (because of its unpleasant taste) in an 
initial dose of 140 mg per Kg, followed by 70 mg /Kg every 4 
hours for 72 hours. 
Treatment with NAC is most effective if given within 8 hours of 
ingestion after which effectiveness declines sharply. It protects 
the liver if given within 10-12 hours of ingestion; NAC may also 
be effective up to and beyond 15 hours but expert advice is 
essential. 
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Treatment with NAC should be started as soon as possible (at the 
latest 12 to 18 hours after ingestion) because once the toxic 
product is produced and the hepatocytes be once damaged, 
treatment will not be effective (Drugs of choice; 1984-1985). 
NAC protects the liver if infused within 24 hours of ingesting 
paracetamol, if more than 24 hours have elapsed advice should be 
sought from a poison information centre or from a liver unit on 
the management of serious liver damage (BNF 52; September 
2006). 
 
 
 
 
 
 
 
 
 
 
 
Figure. 8 paracetamol poisoning symptoms 
(Reproduced from ABC of Poisoning Drugs) 
Acetylcysteine NAC injection: 
By intravenous infusion, in glucose intravenous infusion 5%, 
initially 150 mg/kg in 200 ml, over 15 minutes, followed by 50 
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mg/kg in 500 ml over 4 hours, then 100 mg/kg in 1 liter over 16 
hours (total of 300 mg/kg over 20.25 hours).  This is for adults 
and children over 12 years. 
Children under 12 years body weight (over 20 kg) initially 100 ml 
given over 15 min, then 250 ml over 4 hours, then 500 ml over 16 
hours (total of 150 mg/kg over 20.25 hr) for children body weight 
under 20 kg, initially 3ml/kg given over 15 min, then 7 ml/kg 
over 4 hour then 14 ml/kg over 16 hours. 
For tears deficiency:  Acetylcysteine 5%, hypomellose 35% eye 
drops 3-4 times daily. 
Mucolytic:  NAC 200 mg/sachet, for adults and children over 6 
years, 200 mg in water 3 times daily, usually for 5-10 days but if 
necessary may be extended to 6 months or longer; child up to 2 
ears 200 mg daily, 2-6 years 200 mg daily. 
As food supplements for adults, one vegetable capsule 600 mg 
daily with juice or water and with a carbohydrates  meal (solgar 
vitamin and herb, Leonia, N.juk. 
Optimal levels of supplementation are uncertain, but a 
considerable proportion of the research study on NAC used 250-
1500 mg per day, as it’s the dose for the majority of therapeutic 
benefit. 
1.1.4 Methods for assay of NAC 
The drug is listed in United States pharmacopeia, which 
recommends a liquid chromatography (LC) method for its assay 
in bulk, solutions and combination with 150 pro treatment (United 
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States pharmacopeia 31, 2008), also listed in British 
pharmacopoeia.,1998) which recommends iodometric method 
(titremetric method) by dissolving NAC powder in glacial acetic 
acid and its titration against iodine standard solution, determining 
the end point visually once stable pale yellow color is obtained 
(British pharmacopoeia ,1998). 
Another method for the determination of NAC is by paired – ion 
reversed – phase high performance liquid chromatography. 
1.1.4.1Titremetric method 
NAC in injection was assayed using titremetric method using 
iodine VS. 
                 O                          KI              
 2HS-CH2-CH-C-CH+CH-C-OH+                                                             
             I2 
    NH-C-CH    
2, 6-dichloroquinone -4-chloroimide (DCQ) has numerous 
applications as an analytical reagent.  It has been used for the 
colorimetric determination of some phenolic and thiol containing 
drugs (Figure 14. ) (Pesez and Bartos, 1974) 
 
 
 
 
 
Figure (9) Reaction of DCQ with thiol containing Compounds 
(reported from Pesez and Bartos, 1974). 
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1.1.5 Objectives of the study  
In view of fact that NAC contains a thiol functional group, it was 
deemed useful to develop a colorimetric method using (DCQ) for 
its determination in pure and dosage forms.  Thus, the aim of this 
study is to: 
Develop a new simple spectrophotonetric procedure accurate and 
rapid analysis of NAC using DCQ as a coloring regent. 
Estimate the λmax of the Acetylcysteine complex proposed. 
Study the different experimental parameters affecting color 
production to determine the optimal conditions for the study 
procedure as temperature, solvent, PH, etc. 
Investigate the reaction time, color intensity and stability of the 
proposed product. 
Study the stoichiometry of the reaction by using molar ratio 
method. 
Construct a calibration curve. 
Determine the range of the colorimetric analysis that obeys Beer's 
Lambert law. 
Determine the limit of detection of NAC-DCQ complex. 
Assay NAC commercial dosage forms using proposed method. 
Validate the proposed method. 
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1.2. Aminocaproic acid  
1.2.1.1Definitions 
 Aminocaproic acid ; Aminohexanoic acid Є_aminocaproic acid  
USP232136 NOHC  
 
 
 
 
 
 
Figure (10) Aminocaproic acid structure (Reproduce from 
Aminocaproic acid _Wikipedia, the free encyclopedia; 2009).  
Is a derivative and analogue of the Amino-acid lysine, It’s a 
clinically useful inhibitor of fibrinolysis (Aminocaproic acid 
_Wikipedia, the free encyclopedia; 2009).  
The central process of fibrinolysis is conversion of inactive 
plasminogen to the proteolytic enzyme plasmin. Injured cells 
release activators of plasminogen. plasmin remodels the thrombus 
and limits the extention of thrombosis by proteolytic digestion of 
fibrin (Basic and clinical pharmacology;2001) . 
Regulation of the fibrinolytic system is useful in therapeutics. 
Increased fibrinolysis is effective therapy for thrombotic disease. 
Conversely, decreased fibrinolysis protects clots from lysis and 
reduces the bleeding of hemostatic failure (Basic and clinical 
pharmacology; 2001). 
O 
II HN 
O
H 
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Blood coagulation and thrombus formation must be confined to 
the smallest possible area to achieve local hemostasis in response 
to bleeding from trauma or surgery without causing disseminated 
coagulation or impaired blood flow. Two major systems regulate 
and delineate these processes; fibrin inhibition and fibrinolysis 
(Basic and clinical pharmacology;2001). 
Aminocaproic acid is an antifibrinolytic drug i.e. coagulant drug; 
reinforce the formed clot by inhibiting its lysis (fibrinolysis). 
Plasma contains protease inhibitors that rapidly inactivate the 
coagulation proteins as they escape from the site of vessel injury 
(Basic and clinical pharmacology;2001). 
. Aminocaproic acid competitively inhibits plasminogen 
activation, and to a lesser degree through antiplasmin activity  
(WWW.fda. Gov., 1996; Stefanini. M, Dameshek W; the 
heamatologic disorders. 1962). 
 
1.2.1.2 Physical properties: 
Aminocaproic acid (MWT 131.173 g/mol) crystals from alcohol, 
mp 202 _203 0 C .pka1 4.43; pk2 10.75 freely soluble in water, 
sparingly in methanol .practically insoluble in ethanol, 
chloroform (Merck, et al., 1999). 
1.2.1.3 Pharmacology  
1.2.1.4 Mechanism of action  
when the intrinsic coagulation system is activated ,the fibrinolytic 
system is also set in motion via several endogenous plasminogen 
activators , there are several exogenous activators of fibrinolysis 
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.Plasminogen , a serum β_globulin of MWT 143000, is deposited 
on the fibrin strands  within a thrombus . Plasminogen activators 
are serine proteases and are unstable in circulating blood.  
They diffuse into thrombus and cleave Plasminogen to release 
plasmin (Pharmacology. 1999).    
 
 
Figure (11) the blood coagulation cascade with the sites of 
action of the anticoagulant drugs (Reproduced from. 
Pharmacology; 4th edition Churchill living stone, 1999). 
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Figure (12) Schematic representation of the fibrinolytic 
system (Reproduced from. Basic and clinical Pharmacology; 
8th edition Churchill living stone, 2001). 
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Figure (13) the probable mechanism of vitamin K and the site 
of action of oral anticoagulants (Reproduced from. 
Pharmacology; 4th edition Churchill living stone, 1999). 
 
Aminocaproic acid, being a derivative and analogue of the amino-
acid lysine, makes it an effective inhibitor for enzymes which 
bind that particular residue. Such enzymes include proteolytic 
enzymes like plasmin, the enzyme responsible for fibrinolysis . 
Aminocaproic acid binds reversibly to the kringle domain of the 
enzymogen plasminogen. Thus plasminogen cannot be activated 
(by its activators) to plasmin which then can split fibrin 
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(antifibrinolytic effect ) (Aminocaproic acid _Wikipedia, the free 
encyclopedia; 2009).  
. There is some evidence that Aminocaproic acid has (but to a 
lesser degree) antiplasmin activity( WWW.fda. Gov .,1996; 
Stefanini. M, Dameshek W; the heamatologic disorders., 1962). 
1.2.1.5 Pharmacological actions  
Treatment with Aminocaproic acid enhances hemostasis when 
fibrinolysis contributes to bleeding. 
Fibrinolytic bleeding may frequently  be associated with surgical 
complications following heart surgery (with or without cardiac by 
pass procedures) and portacaval shunt; hematological disorders 
such as aplastic anemia , abruptio placentae, hepatic cirrhosis, 
neoplastic disease such as carcinoma of prostate ,lung ,stomach 
and cervix (WWW.fda. Gov .,1996; Stefanini. M, Dameshek W; 
the heamatologic disorders., 1962).  
Aminocaproic acid competitively inhibits plasminogen activation, 
thus i.e. reinforce the clot formed and preserve it. 
 
1.2.1.6 Pharmacokinetics of Aminocaproic acid  
Aminocaproic acid rapidly absorbed orally, in adult’s oral 
absorption appears to be a zero order process with an absorption 
rate of 5.2g/hour. 
The mean lag time in absorption is 10 minutes. 
  After a single oral dose of 5 g, absorption was complete 
(f=1).Mean ± SD peak plasma concentrations (164±28 mcg/ml) 
were reached within 1.2±o.45 hours. 
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After oral administration, the apparent volume of distribution was 
estimated to be 23.1±6.6 L (Mean ± SD). Correspondingly, the 
volume of distribution after I.V administration has been reported 
to be 30.0±8.2 L. 
After prolonged administration, Aminocaproic acid has been 
found to distribute through out extra vascular and intravascular 
compartments of the body Penetrating human red blood cells as 
well as other tissue cells. 
Renal excretion is the primary route of elimination, whether 
aminocaproic acid orally or intravenously .65% of the dose is 
recovered in the urine as unchanged drug and 11% of the dose 
appears as the metabolic adipic acid. Renal clearance (116 
ml/min) approximates endogenous creatinine clearance. The total 
body clearance is 169 ml/min. The terminal elimination half-life 
for Aminocaproic acid is approximately 2 hours (WWW.fda. Gov 
.,1996; Stefanini. M, Dameshek W; the heamatologic disorders., 
1962).  
1.2.1.7 Indications of aminocaproic acid  
Aminocaproic acid is indicated as adjunctive therapy in 
hemophilia and hemophilic patients to treat their bleeding after 
dental extractions because the oral mucosa is rich in plasminogen 
activators , as therapy for bleeding from fibrinolytic therapy , and 
as prophylaxis for bleeding from intracranial aneurysms. 
Other uses of Aminocaproic acid is that it is occationally used in 
BN_Page buffers, not for its effects as proteolysis inhibitor, but to 
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solubilize membrane proteins in place of NACL (which is in 
compatible with page in the necessary concentration).percent 
recovery of protein complexes increases linearly with the 
concentration of inhibitor (between 125 mM and 750 mM) 
(Aminocaproic acid _Wikipedia, the free encyclopedia; 2009).  
Treatment success has also been reported in patients with post 
surgical gastrointestinal bleeding and post prostatectomy bleeding 
and bladder hemorrhage secondary to radiation _and drug_ 
induced cystitis. 
Aminocaproic acid is useful in enhancing hemostasis when 
fibrinolysis contributes to bleeding. 
Fibrinolytic bleeding may frequently be associated with surgical 
complications following heart surgery (with or without cardiac by 
pass procedures )  a meta analysis found that lysine analogue like 
aminocaproic acid significantly reduced blood loss in patients 
undergoing coronary artery by pass grafting . and portacaval 
shunt  ;  hamatological disorders such as aplastic anemiac , 
abruptio placentae ,hepatic cirrhosis , neoplastic disease such as 
carcinoma of the prostate ,lung , stomach and cervix. 
Urinary fibrinolysis , usually a normal physiological 
phenomenon, may frequently be associated with life _ threatening 
complications following severe trauma , anoxia , and shock . 
Symptomatic of such complications is surgical hematuria  
(following  prostatectomy and nephrectomy) or non _surgical 
hematuria ( accompanying polycystic or neoplastic disease of the 
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genitourinary system ) ((WWW.fda. Gov .,1996; Stefanini. M, 
Dameshek W; the heamatologic disorders., 1962).  
 
1.2.1.8 Side effects of aminocaproic acid  
Aminocaproic acid is generally well tolerated, but the following 
adverse experiences have been reported, generally edema, 
headache and malaise have been reported. Allergic and 
anaphylactic reactions include anaphylaxis local reactions such as 
injection site reactions. 
In cardiovascular system; bradycardia, hypotension, periveral 
ischemia and thrombosis. In GIT; abdominal pain, diarrhea, 
nausea and vomiting. Hematological reactions include 
agranulocytosis . Coagulation disorder; include intravascular 
thrombosis from inhibition of plasminogen activator, leucopenia 
and tthrombocytopenia . 
Muscloskletal reactions include increased creatinine 
phosphokinase cpk , muscle weakness , myalgia , myopathy , 
myositis  and rhabdomyolysis  
Neurological reactions include confusion, convulsions, delirium, 
dizziness, hallucinations, intracranial hypertentoin, stroke, 
syncope. 
Respiratory reactions include dyspnea, nasal congestion 
pulmonary empolism. 
Skin senses reactions include tinnitus, vision decreased and 
watery eyes  
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Urogenital reactions include BUN increased, renal failure, ther 
have been some reports of dry ejaculation during the period of 
aminocaproic acid treatment. There have been reported to date 
only in hemophilia patients who received the drug after 
undergoing dental surgical procedure. However, these symptoms 
resolved in all patients within 24 hours to 48 hours of completion 
of therapy ((WWW.fda. Gov .,1996; Stefanini. M, Dameshek W; 
the heamatologic disorders., 1962).  
 
1.2.1.9 Aminocaproic acid dosage forms  
Aminocaproic acid is available as :  
Tablets; 0.25 g, 0.5 g  
Syrup; USP containing 1.25 g\5 ml  , 0.25 g/ ml ( syrup 25% ) in 
bottles 118  ml and 473 ml  by MIKAT, INC. 
Injection; containing 0.25 g /ml for IV injection or 5 g/20 ml by 
American Reagent Inc. 
1.2.1.10 Dosage of aminocaproic acid  
For treatment of acute bleeding syndrome due to elevated 
fibrinolytic activity , it is suggested that 4 teasponfuls ( 5 g )of 
aminocaproic acid syrup ( 1.25 *4 = 5 g ) be administrated during 
the first hour of treatment followed by a continuing rate of 1 
teasponful ( 1.25 g ) of syrup / hour . This method of treatment 
would ordinarily be continued for about 8 hours or until the 
bleeding situation has been controlled. 
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10 g / day orally or 6 g IV initially and then 6 g over 24 hours up 
to 0.2 g / Kg ( WWW.fda. Gov., 1996; Stefanini. M, Dameshek 
W; the heamatologic disorders, 1962). 
The usual oral dosage of EACA is 6 g four times a day, when the 
drug is administered intravenously , a 5 g loading dose should be 
infused over 30 minutes to avoid hypotension (Principles of 
medicinal chemistry;1989., William .O. Foye). 
1.2.2 Methods of assay of ACA 
The drug is listed in analytical abstracts under the heading solid 
phase extraction of horse urine of 6-aminocaproic acid , The 
method suggested determination of ACA by either TLC, GC_MS 
or HPLC after derivatisation with flourescamine 
(Chromatographia. Sep 1990). 
The drug is also listed under HPLC assay of amicar, in plasma 
and urine fluid after pre-column derivatisation with  
O-phthalaldehyde for fluorescence detection (Biomed-
chromatogr. Jul 1990). 
1.2.3 Objectives of the study: 
The aim of this study is to: 
Develop a new simple spectrophotonetric procedure accurate and 
rapid analysis of ACA using ascorbic acid as a chromogen. 
Estimate the λ max of the ACA-ascorbic acid complex proposed. 
Study the different experimental parameters affecting color 
production to determine the optimal conditions for the study 
procedure as temperature, solvent, PH, etc. 
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Investigate the reaction time, color intensity and stability of the 
proposed product. 
Study the stoichiometry of the reaction by using molar ratio 
method. 
Construct a calibration curve. 
Determine the range of the colorimetric analysis that obeys Beer's 
Lambert law. 
Determine the limit of detection of ACA-ascorbic acid complex. 
Assay ACA commercial dosage forms using proposed method. 
Validate the proposed method. 
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CHAPTER TWO 
METHODS 
2.1.Methods for NAC: 
2.1.1Materials, reagents and instrument. 
2.1.1.1Materials. 
The materials and their sources are summarized in table 1. 
 
Table (1):  Materials: 
Chemical Company Country
Parvolex ® solution for 
infusion 10 ml acetyl 
cysteine ph. Eur. 2g/10ml 
(200 mg/ml) 
Batch No. 517774 
Manufacture date: 
Expiry date:  11/2008 
UCB pharma limited UK 
NAC (N-Acetylcysteine 600 
mg vegetable capsules 
Batch No.  60384503 
Manufacture date: 
Expiry date:  3/2010 
SOLGAR Vitamins 
and Herb, Leonia, N. J 
for: Solgar Vitamin 
and Herb (U.K) 
USA 
 
2.1.1.2Reagents. 
All chemicals and reagents used were of analytical grade and 
were used without further purification.  They are listed in table2: 
reagents. 
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Table (2):   Reagents 
Chemical Company Country 
2,6- dichloroquinone 
-4-chloroimide DCQ 
Merck KGA Germany 
N- N-Acetylcysteine RS 
Gehalt as 99.4% 
Merck KGA Germany 
Ethyl alcohol (absolute) Media lab India 
Potassium Iodine (extra 
pure) 
S.D fine chem. 
Limited 
India 
Acetic acid glacial (extra 
pure) 
S.D fine chem. 
Limited 
India 
Iodine resublimed BDH England 
Glycine Blulux® Regent India 
Sodium acetate   
Sodium hydroxide BDH England 
Disodium hydrogen 
orthophosphate 
Hopkins and 
Williams Ltd. 
England 
Potassium dihydorgen 
phosphate 
British Drug House 
BDH 
England 
Dimethyl sulfoxide LOBA Chemic Ltd. India 
L-cysteine Sd. Five Chem Ltd. India 
L-phenyl Alamine S.D Fine Chem Ltd. India 
L-Tyrosine S.D. Fine Chem Ltd. India 
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2.1.1.3 Instrument: 
2.1.1.3.1 Ultraviolet/visible spectrophotometer. 
2.1.1.3.1 Perkin Elmer spectrophotometer:- 
Visible spectra were obtained using a Perkin Elmer 
spectrophotometer, Lambda 2 and 1 cm quartz cuvettes.  The 
instrument was obtained from Perkin Elmer Ltd. Beaconsfield, 
Buckinghamshier.                                                                                               
2.1.1.3.3 PH meter: 
PH was adjusted using a jen way 3510 PH meter model: 3510.  
The instrument was designed and manufactured in Europe by 
Barlow World Scientific, Ltd. Dunmow, Esex CM6, and 3LB. 
2.1.1.3.4 Balance: 
Samples and reagents were weighed using a KERAN balance 
KERAN ALS 120-4. The instrument was obtained from kern and 
sohn Gm bH, D-72336 Balingen, Germany. 
2.1.1.3.5 Water Path: 
Samples and reagents were heated in water path type GFL, 
Gesellschaft fữr labortechink mbh , D-309838, Germany. 
 
2.1.1.4 Reagents and samples stock preparation   
2.1.1.4.1 Preparation of 2, 6-Dichloroquinone – 4-Chloroimide 
(DCQ) solution. 
0.025 g of DCQ powder was weighed, dissolved in 2-3 ml 
absolute ethanol and transferred to 10 ml volumetric flask and the 
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volume was completed to mark with absolute ethanol in which the 
final solution contains 2500 microgram/ml (0.25% w/v). 
Working `solution B. 
2.1.1.4.2 Preparation of 2, 6 dichloroquinine-4- chloroimide 
for stoichiometry. 
0.0165 g of  DCQ  powder was weighed, dissolved in 2-3 ml of 
absolute ethanol, and transferred into 50 ml volumetric flask and 
the volume was completed to mark with absolute ethanol in which 
the final solution contains 0.033% W/V or 830 µg/ml working 
solution A. 
2.1.1.4.3 Preparation of 2.6-Dicholoroquinone-4-chloroimide 
(DCQ) fresh solution for stiochiometry:  
0.035 g of  DCQ powder was weighed, dissolved in 2-3 ml of 
absolute ethanol and transferred into 10 ml volumetric false and 
the volume was completed to mark with absolute ethanol in which 
the final solution contains (0.35% w/v  0.033% w/v or 830 µg/ml 
working solution A.0.035 g of DCQ powder was weighed, 
dissolved in 2-3 l of absolute ethanol, and transferred into 10 ml 
volumetric flask and the volume was completed to mark with 
absolute ethanol in which the final solution contains (0.35% w/v 
3500 microgram/ml working solution C. 
2.1.1.4.4 Preparation of 2, 6 –dichloroquinone -4-chloroimide: 
0.05 g of DCQ powder was weighed, dissolved in 2 – 3 ml of 
absolute ethanol and transferred into 10 – 1 volumetric flank with 
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absolute ethanol in which the final solution contains (0.5% w/v 
5000 µg/ml) working solution  D. 
 
2.1.1.4.5 N-acetyl cysteine RS 
Stock solution (150 µg/ml) 0.015 g NAC RS was weighed using a 
sensitive calibrated digital balance, dissolved in 50 ml absolute 
ethanol and transferred into 100 ml volumetric flask and the 
volume was completed to the mark with distilled water in which 
the final solution contains 150 mg/ml (0.015 % NB = solvent is 
50:50 absolute ethanol and dishwater working solution E. 
2.1.1.4.6 NAC RS stock solution (250 µg/ml) 
 0.0 25g of NAC RS was weighed using a sensitive calibrated 
digital balance, dissolve in about 50ml absolute ethanol and 
transferred into 100 ml volumetric flask and the volume was 
completed to the mark with distilled water in which the final 
solution contains 250 µg/ml (0.025% w/v working solution F. 
2.1.1.4.7 Phosphate buffer solution (PH-7) 
Two methods: 
2.1.1.4.7.1 Method A: 
0.942 g of potassium dihydrogen or the phosphate was weighed 
using sensitive balance, transferred into 200 ml volumetric flask, 
and 1.59 g of dissolution hydrogen phosphate was weighed using 
sensitive balance, it was transferred to the same volumetric flask 
containing KH2PO4, then distilled water 2-3 ml was added, 
shaken to be mixed and the volume was completed to 200 ml with 
distilled water. 
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2.1.1.4.7.2 Method B: 
50 ml of a 13.6% w/v solution of  potassium hydrogen 
orthophosphate was mixed with 29.5 ml of IM sodium hydroxide 
and then the mixture was dilute was diluted to 100 ml with water. 
The solution PH was adjusted to 7.0 using IM sodium hydroxide 
solution (British pharmacopoeia, 2005). 
2.1.1.4.8 Parvolex® sample solution 
Injection 2 gram/10 ml; 2ml of sample parvolex® solution were 
taken, transferred to 100 ml volumetric flask. 
The volume was completed to mark with   (100 ml mixture of 
50:50  distilled water and absolute ethanol, then 5 ml was taken, 
(transferred to 100 ml volumetric flask and the volume was 
completed to mark with  mixture 50:50 absolute ethanol and 
distilled water.  In which the final concentration was 200 
µg/ml.Working solution G. 
2.1.1.4.9 Preparation of parvolex ® 100 µg/ml sample solution 
1m1 of parvolex ® sample solution was taken, transferred to 100 
ml volumetric flask, the volume was completed to the mark with 
50:50 mixture absolute ethanol and distilled water, 5 ml was then 
taken, transferred to 100 ml volumetric flask, and the volume was 
completed to mark with 50:50 mixture of absolute ethanol and 
distilled water (fresh ethanol) in which the final concentration 
was (100 µg/ml) Working solution H. 
 
 
 46 
2.1.1.4.10 preparation of parvolex® 250 µg/ml sample 
solution. 
2.5 ml of parvolex® sample solution was taken, transferred into 
100 ml volumetric flask , the volume was completed to mark with 
mixture 50:50 absolute alcohol and distilled water 5 ml was 
taken, transferred into 100 ml volumetric flask , the volume was 
completed to mark with mixture 50:50 absolute alcohol and 
distilled water  working solution J . 
2.1.1.4.11 Preparation of NAC 600 mg vegetable capsules 
sample solutions: 
The contents of 5 capsules of NAC 600 mg capsules were 
accurately weighed and the main value of weight of one capsule 
was calculated, an amount of NAC powder equivalent to (25) mg 
of NAC were accurately weighed after emptying, and powdering 
capsules respectively.  The weighed powder were transferred into 
100 ml volumetric flasks  a mixture of 50:50 absolute ethanol and 
distilled water was added, the volume completed to reach the 
mark; in which NAC 600 mg vegetable capsule solutions 
theoretically contains 250 µg/ml .Working solution K. 
2.1.1.5 Methods 
2.1.1.5.1 Effects of different solvents on absorption spectra:  
2.1.1.5.1.1 DMSO with acetate  
    3, and 3 ml of solution E (150 mg/ml NAS RS) was taken, 
transferred into two 25ml volumetric flask. 2 ml of (mixture 
50:50 absolute ethanol and distilled water). Then 13 ml of 
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dimethyl sulfoxide DMSO was added.  1m of sodium acetate 1% 
was added.  Also 1ml of solution B was added.  The volume 
(NAC RS = 30 µg/ml) was completed to mark with distilled 
water.  BLK was 5 ml of (absolute ethanol) was taken transferred 
into 25 ml volumetric flask then 13 ml of DMSO was added.  1ml 
of acetate 1% was added.  1 ml of solution B was added. The 
volume was completed to mark with distilled water. 
2.1.1.5.1.2 DMSO without acetate  
To the other 3 ml of solution F, 2 ml of absolute ethanol was 
added .Then 1ml of solution B was added.  The volume was 
completed to mark with distilled water final concentration: 30 
µg/ml NAC RS. 
Blank was prepared similarly but without using solution F. 
Process was repeated two times. 
2.1.1.5.2 Effects of PH on absorption spectra: 
2.1.1.5.2.1 PH 3.5 
 5 ml of solutions of both drug and standard (F, K) (250 µg/ml) 
were taken transferred into two 25 ml volumetric flask.  2 ml of 
(mixture 50:50 absolute ethanol and distilled water) was added.  1 
ml of sodium acetate (PH 3.5) was added.  Then 1ml of solution 
B was added to each flask.  Then the volume was completed to 
mark with distilled water.  The final solution contains 50 µg/ml 
NAC RS. This process was repeated three times.  
Blanks were prepared similarly but without using solutions (F, 
K). 
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2.1.5.2.2 PH 7 
5 ml of solutions of both drug and standard (F,K) (250 µg/ml) 
were taken, transferred into two 25 ml volumetric flasks, 2ml of 
mixture 50:50 absolute ethanol and distilled water was added.1 ml 
of phosphate buffer (PH 7) was added to each .Then 1 ml of 
solution B was added . The volume was completed to mark with 
distilled water in which the final solution contains 50 µg/ml NAC 
RS. This process was repeated six times. 
Blank was prepared similarly but without using solutions (F, K).  
2.1.1.5.3 Effects of different weights of standard (freshly 
prepared standard and acetate) 
0.02g, 0.035, 0.05 and  0.075g of  standard  was  taken  dissolved 
in 50ml distilled water and volume was  complete to mark 
(100ml) with  absolute ethanol. Then  3ml of these  stocks were 
each taken, 2 ml of  mixture  50:50 distilled  water  to  absolute 
ethanol was added then 1m1 of freshly  prepared 1% sodium  
acetate  solution was also added followed by  1 ml of fresh 
solution B volume  was completed  to 25ml with distilled water 
2.1.1.5.4 Construction of calibration Curve:  
Aliquot volumes (1-5) ml of solution F (250 µg/ml) were each 
transferred into 25 ml volumetric flasks. A volume mixture 50:50 
absolute ethanol and distilled water was added to each flask to 
adjust the volume to 5 ml using volumetric pipette, then 1 ml of 
solution B (0.25% w/v) was added to each flask. The volume was 
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completed to make with mixture 50:50 absolute ethanol and 
distilled water. 
Blank was prepared similarly but without using solution F (Table 
3). 
The absorbance was measured at 438 nm against its blank.  The 
absorbance was plotted against the final concentration in order to 
obtain a calibration graph. 
This procedure was repeated 3 times to obtain triplicate standard 
curve readings. 
Table (3):  NAS RS solution for construction of calibration 
curve 
 
Solution 
No 
Solution f 
(m1) 
Mixture 
(ml) 
Solution 
(B) 
Acetate Mixture 
(ml) 
NAC RS 
concentration 
(µg/ml) 
1-1 1.00 4.00 1.00 1 18.00 10.00 
1-2 1.00 4.00 1.00 1 18.00 10.00 
1-3 1.00 4.00 1.00 1 18.00 10.00 
2-1 2.00 3.00 1.00 1 18.00 20.00 
2-2 2.00 3.00 1.00 1 18.00 20.00 
2-3 2.00 3.00 1.00 1 18.00 20.00 
3-1 3.00 2.00 1.00 1 18.00 30.00 
3-2 3.00 2.00 1.00 1 18.00 30.00 
3-3 3.00 2.00 1.00 1 18.00 30.00 
4-1 4.00 1.00 1.00 1 18.00 40.00 
4-2 4.00 1.00 1.00 1 18.00 40.00 
4-3 4.00 1.00 1.00 1 18.00 40.00 
5-1 5.00 0.00 1.00 1 18.00 50.00 
5-2 5.00 0.00 1.00 1 18.00 50.00 
5-3 5.00 0.00 1.00 1 18.00 50.00 
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2.1.1.5.5 Construction of NAC 600mg vegetable capsules 
curve.     
 This procedure was repeated two times to obtain duplicate 
standard curve reading. 
Table (4): NAC 600 mg vegetable capsules solutions for 
construction of calibration curve  
 
No Solution 
m (m1) 
Mixture 
(ml) 
Solution 
B (ml) 
Acetate 
1% (ml)
Mixtur
e (ml) 
NAC 
vegetable 
capsules 
concentrati
on (µg/ml) 
1-1 1.00 4.00 1.00 1 18.00 10.00 
1-2 1.00 4.00 1.00 1 18.00 10.00 
2-1 3.00 2.00 1.00 1 18.00 30.00 
2-2 3.00 2.00 1.00 1 18.00 30.00 
3-1 5.00 0.00 1.00 1 18.00 50.00 
3-2 5.00 0.00 1.00 1 18.00 50.00 
 
2.1.1.5.6 Assay Using NAC RS, parvolex ® and NAC 600 mg 
vegetable capsules solutions  
Three different solutions of NAC RS, parvolex and solgar NAC 
600 mg vegetable capsules were prepared similarly at the same 
time .the absorbance of each solution was measured at 438 nm 
against its blank. 
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2.1.1.5.7 Preparation of solution NAC RS  
3 ml of solution f (250 µg/ml)   was taken transferred into 25 ml 
volumetric flask; 2 ml of mixture {50:50 absolute ethanol and 
distilled water} was added. 1 ml of solution b (0.25 %w/ v) 1 ml 
of sodium acetate 1% was added. The volume was completed to 
mark with mixture 50; 50 absolute ethanol and distilled water. 
Blank was prepared similarly but without using solution  
2.1.1.5.8 Preparation of parvolex ® solution 
3 ml of solution G (200 µg/ml) was transferred into 25 ml 
volumetric flask. 2 ml of mixture 50:50 absolute ethanol and 
distilled water was added. 1 ml of solution B was added and 1 ml 
of sodium acetate 1% .the volume was completed to mark with 
mixture 50:50 absolute ethanol and distilled water. 
2.1.1.5.9 Preparation of NAC 600 mg vegetable capsule 
solution  
3 ml of solution K (250 µg/ml) were taken transferred into 25 ml 
volumetric flask. 2 ml of mixture 50: 50 absolute ethanol and 
distilled water was added, 1 ml of solution b was added, and 1 ml 
of acetate 1% was also added. The volume was completed to 
mark with distilled water. 
-4
 52 
2.1.1.6 Stoichiometry  
2.1.1.6.1 Molar ratio method  
2.1.1.6.1.1 Fixed DCQ concentration against different NAC 
concentration  
0.0165 g of DCQ powder was weighed, dissolved in 2_3 ml of 
absolute ¹completed to mark with absolute ethanol in which the 
final solution contains 1.57 *10-3 m  
0.0125 g of NAC 600 mg vegetable capsules was weighed, 
transferred into 50 ml volumetric flask and processed as above. 
Aliquot volumes (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, and 5 ml of 
solution N (250 µg/ml) were each transferred into ten 25 ml 
volumetric flasks. A volume of mixture 50:50 absolute ethanol 
and distilled water was added to each flask to adjust the volume to 
5 ml using volumetric pipette, then 1 ml of sodium acetate 1% 
was added to each flask. The volume was completed to mark with 
mixture 50:50 absolute ethanol and distilled water. 
 Blank was prepared similarly but without using solution n.  
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Table (5): Fixed DCQ concentration against different NAC 
concentration  
Standard 
volume (ml) 
Standard 
conc. (µg/ml) 
DCQ 
volume 
(ml) 
DCQ conc. 
(µg/ml) M 
0.5 5 2.5 33          1.57×10 -4 
1 10 2.5 33 1.57×10 -4 
1.5 15 2.5 33 1.57×10-4  
2 20 2.5 33 1.57×10 -4
2.5 25 2.5 33 1.57×10-4  
3 30 2.5 33 1.57×10-4  
3.5 35 2.5 33 1.57×10-4  
4 40 2.5 33 1.57×10-4  
4.5 45 2.5 33 1.57×10-4  
5 50 2.5 33 1.57×10-4  
 
2.1.1.6.2 Fixed NAC Concentration Against different DCQ 
concentration. 
0.0164 g of DCQ powder was weighed , dissolved2-3 ml of 
absolute ethanol , transferred into 50 ml volumetric flask , then 
volume completed to mark with absolute ethanol in which the 
final solution contains 1.5 *10 to the power -3 M 
Aliquot volumes (0.5,1,1.5,2,2.5,3,3.5,4,4.5 and 5 ml )of above 
solution was taken , transferred into ten 25 ml volumetric flasks 
.the volume was completed to 5 ml with absolute ethanol . 2.5 ml 
of solution (250 NAC µg/ml was added to each flask; 1 ml of 
acetate 1%was added. The volume was completed to 25 ml with 
distilled water. 
Blanks were prepared similarly but without using solution n. 
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The absorbance was measured at 438 nm against their blanks. The 
absorbance was plotted against the final concentration in order to 
obtain a graph.  
Table (6): Fixed NAC Concentration Against different DCQ 
concentration. 
 
volume 
(ml) 
DCQ 
conc. 
(µg/ml) 
Standard 
volume (ml)
Standard conc. 
(µg/ml) M 
0.5 6.56 2.5 25 1.53×10-4  
11.5 13.12 2.5 25 1.53×10-4  
2 19.68 2.5 25 1.53×10-4  
2.5 26.24 2.5 25 1.53×10-4  
 32.8 2.5 25 1.53×10 -4 
3.5 39.36 2.5 25 1.53×10-4  
4 45.92 2.5 25 1.53×10-4  
4.5 52.48 2.5 25 1.53×10-4  
5 59.04 2.5 25 1.53×10-4   
 
 
2.1.1.7 Titremetric method 
2 ml of parvolex ® injection was taken ( equivalent to 0.4 g of 
NAC)  put in 1oo ml volumetric flask , then 20 ml of glacial 
acetic acid was added to it , then a volume of about 30 ml of 
0.049 M iodine VS was put in volumetric pipette , it was added 
slowly to the solution in the volumetric flask till a permanent pale 
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yellow color is obtained , the volume of 0.049 M iodine VS was 
recorded in the results.     
2.1.1.8 Added recovery  
0.0246 g of DCQ powder was weighed dissolved in 2-3 ml of 
absolute alcohol and the volume was completed to 10 ml. A 
weight of NAC 600 mg vegetable capsules equivalent to 0.025 g 
was aquarately weighed dissolved in 2-3 ml of mixture (50:50 
absolute ethanol and distilled water) the volume was completed to 
100 ml with the same mixture. 0.025 g of NAC was weighed 
processed as the capsules above. 2 ml of both solutions of drug 
and standard was transferred into two 25 ml volumetric flasks, 
then the volume was completed to 5 ml with mixture. .  . 2 ml of 
solution of standard was put in 25 ml volumetric flask then 2 ml 
of solution of drug was added to it then 1ml of mixture was added 
to it1 ml of sodium acetate 1% was added to both then 1 ml of 
DCQ solution was added to both then the volume was completed 
to mark with mixture. This process was repeated six times.      
2.1.1.9 Interference: 
Small amounts of each of L-cysteine, L-phenylalanine and L- 
tyrosine were taken, dissolved in aliquot volumes of mixture 
(50:50 absolute ethanol and  distilled water ), then 1 ml of DCQ 
in absolute ethanol was added to each , results were observed and 
recoded. 
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2.2 Methods for ACA 
2.2.1 Materials, Reagents, and instruments  
2.2.1.1 Materials  
The materials used and their sources are summarize in table (7). 
Table (7) Materials: 
Chemical Company Country 
Aminocaproic acid injection 
(205 mg/20 ml  
(5mg/20ml) 
Lot No. 6489 
Expiry date. 7.2009 
American 
Reagent Inc 
Ny. USA  
2.2.1.2 Reagents: 
All chemicals and reagents used were analytical grade and were 
used without any further purification. They are listed in table (2). 
Table (8) Reagents: 
Chemical Company Country
A minocaproic acid RS Sigma Aldrich China  
L-Ascorbi acid LR  
Product No. 54006 
S.d finechem limited  India  
Dimethyl sulfoxide DMSO LOBA Chemic Ltd. India 
Dimethyl formamide DMF TECHNO 
pharmachem 
India 
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2.2.1.3 Reagent & Samples Stock Preparation:  
2.2.1.3.1 Preparation of L. Ascorbic acid Standard stock 
solution:  
0.01 g of l_ascorbic acid powder was weighed dissolved in 0.1 ml 
of distilled water then volume completed to 10 ml with DMSO in 
which the final solution contains 0.1% w/v of ascorbic acid  
( solution A) . 
2.2.1.3.2 Preparation of aminocaproic acid standard solution  
0.1 g of standard aminocaproic acid powder was weighed put in 
50 ml volumetric flask dissolved in 10 ml distilled water and then 
40 ml of DMSO was added to complete the volume to the mark 
(solution B). 
2.2.1.3.3 Preparation of solvent solution: 10 ml of distilled 
water was taken by bulk pipette transferred into 50 ml volumetric 
flask then 40 ml of DMSO was added to it referred to as solution 
(C). 
2.2.1.3.4 Preparation of aminocaproic acid standard solution 
for calibration curve: 
Serial dilutions were made from solution B.100 µl, 80 µl, 60 µl, 
40 µl and 20 µl of this solution were transferred into Stoppard 
glass tubes, then 20 µl, 40 µl, 60 µl, 80 µl and 0.00 µl of distilled 
water were added to each tube to produce 100 µl (maximum 
aqueous volume).Two ml of freshly prepared solution A 
(0.01%w/v ascorbic acid in DMSO) was added to each tube , the 
volume was completed to 10 ml with DMSO,  Then it was put in 
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boiling water path for 30 minutes then cooled using tap water. 
The absorbance was measured at390 and 530nm against a reagent 
blank. The graphs were constructed by plotting the absorbance 
values versus drug concentration at each wave length.    
2.2.1.3.5 Preparation of aminocaproic acid sample (injection) 
solution:  
0.4 ml of injection was taken directly, 10 ml of distilled water was 
added to it then 40 ml of DMSO was also added. Referred to as 
solution (D). It was then processed as in calibration curve above. 
2.2.1.3.6 Preparation of standard ACA solution for stability  
0.1 g of standard ACA powder was weighed dissolved in 10 ml 
distilled water and 40 ml of DMSO was added, then it was 
processed as in solution B above (2.2.1.4.4).  The corresponding 
absorbance was measured against its blank and then solution was 
left in dark place for 16 hours and then absorbance was measured 
and compared to that at starting to see the stability of solution. 
2.2.1.3.7 Preparation of sample (injection) ACA solution for 
stability  
0.4 ml of ACA injection was taken without further dilution to it 
10 ml of distilled water was added and then 40 ml of DMSO was 
added. It was then processed as in standard solution above. The 
corresponding absorbance was measured against its blank and 
then solution was left in a dark place for 22 hours and then 
absorbance was measured and compared to that at starting to see 
the stability of the solution. 
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 2.2.1.3.8 Effect of boiling time on reaction of ascorbic acid 
with ACA 
 0.1 g of ACA standard powder was weighed processed as in 
2.2.4 above, each concentration was repeated four times and then 
four blanks were also prepared then in the boiling water path, the 
boiling time varied from 10, 20, 30 and 40 minutes prior to 
cooling with tap water then the corresponding absorbance was 
measured for each group, results were tabulated  
2.2.1.3.9 Effect of different concentrations of ascorbic acid on 
reaction of ascorbic acid with ACA. 
0.005 ,o.o1 ,0.015 and 0.02  g of ascorbic acid powder was 
weighed , to each 0.1 ml of distilled water was added , and then 
10 ml of DMSO was added to each , they were referred to as E, F, 
g, and H .  
0.1 g of standard ACA powder was weighed dissolved in 10 ml 
distilled water and then 40 ml of DMSO was added , 0.1 ml (20  
µg ACA ) of this stock was taken four times  transferred into four 
10 ml volumetric flasks they were labeled (i), (ii) , (iii) and (iv) . 
2 ml of fresh solutions E, F, G, and H were added to each flask 
respectively and then 8 ml of DMSO was added to each to 
complete the volume to 10 ml. Blanks were four prepared 
similarly but with out using standard solution .They were put in 
boiling water path for 30 minutes and then cooled using tap water. 
The absorbance of each of the four solutions was measured 
against its blank, results were tabulated.  
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2.2.1.3.10 Blank signal 
 0.1 ml of distilled water was taken transferred into 10 ml 
volumetric flask , 2 ml of fresh  solution A was added and 8 ml of 
DMSO was added , it was put in boiling water path for 30 
minutes and then cooled using tap water,  absorbance of this 
solution was run against distilled water . 
2.2.1.3.11 Molar ratio method:  
2.2.1.3.11.1Trial no (1)  
0.0351 g of ascorbic acid was weighed, 0.1 ml of distilled water 
was added to it, and then 2 ml of DMSO was also added referred 
to as solution (Q). 0.0163 g of standard ACA was weighed 
dissolved in 5 ml of distilled water referred to as solution(R).10, 
20, 30, 40 ,50, 60, 70 ,80, 100 and zero µl of solution R was 
taken, to each 90, 80, 70, 60, 50, 40, 30, 20 ,zero and 100 µl of 
distilled water was added , then 50 µl of solution Q was added to 
each of them , then 10 ml of DMSO was added .they were put in 
boiling water path for 30 minutes and then cooled using tap water. 
Their absorbance was measured against their blank. 
2.2.1.3.11.2 Trial no (2) 
0.0352 g of ascorbic acid was weighed, 0.1 ml of distilled water 
was added to it, and then 2 ml of DMSO was also added referred 
to as solution (S). 0.0327 g of standard ACA was weighed 
dissolved in 5 ml of distilled water referred to as solution (T), 
5,10,15,20,25,30,40, and 50 µl of solution T was taken.  45, 40, 
35,30,25,20,10,zero and 50 µl of distilled water was added , then 
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50 µl of solution S was added to each of them , then 10 ml of 
DMSO was added .they were put in boiling water path for 30 
minutes and then cooled using tap water. Their absorbance was 
measured against their blank. 
2.2.1.3.12 Preparation of ACA solutions for added recovery: 
2.2.1.3.12.1 Preparation of standard ACA solution for added 
recovery: 
0.1g of ACA standard powder was weighed processed as in 2.2.4 
above, 4 ml of this fresh solution was transferred into 10 ml 
volumetric flask then 6 ml of solution C was added. 0.1 ml of this 
solution was taken three times transferred into three 10 ml 
volumetric flask then 2 ml of fresh solution B was added  to each 
of them then volume completed to mark with 8 ml DMSO in 
which the final solution contains 8 µg per ml of ACA. They were 
put in boiling water path for 30 minutes and then cooled using tap 
water. Their absorbance was measured against their blank. 
 
2.2.1.3.12.2 Preparation of sample (injection) ACA solution 
for added recovery: 
Injection was diluted with distilled water to 10 ml i.e.6 ml 
distilled water was added to it (here 1 ml contains 0.1 g of ACA) 
heating and then shaking was done for injection to aid its 
solubility .Then 1 ml of injection was taken, to it 10 ml   of 
distilled water was added to it then 40 ml of DMSO was also 
added this solution was heated and after cooling directly   4 ml of 
this fresh solution was transferred into 10 ml volumetric flask 
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then 6 ml of solution C was added heating was also done at this 
stage . 0.1 ml of this solution was taken three times transferred 
into three 10 ml volumetric flask then 2 ml of fresh solution B 
was added  to each of them then volume completed to mark with 
8 ml DMSO in which the final solution contains 8 µg per ml of 
ACA. They were put in boiling water path for 30 minutes and 
then cooled using tap water. Their absorbance was measured 
against their blank. 
2.2.1.3.12.3 Preparation of mixture (standard +injection of 
ACA) solution for added recovery: 
4 ml of solution of standard (2.2.3.1) was taken, transferred into 
10 ml volumetric flask, then 4 ml of injection solution (2.2.3.2) 
was firstly heated then waited to cool then added to the 4 ml of 
standard solution, then 2 ml of fresh solution C was added to 
them then heated then wait to cool then 0.1 ml of this solution 
was taken four times, transferred into four 10 ml volumetric 
flasks, 2 ml of fresh solution B was added to each of them  then 
volume completed to mark with 8 ml DMSO in which the final 
solution contains 8 µg per ml of ACA. They were put in boiling 
water path for 30 minutes and then cooled using tap water. Their 
absorbance was measured against their blank. Percentage added 
recovery of ACA was calculated as follows: 
(At - Asm)/ Astd × 100 
Where At = total absorbance of mixture (sample + mixture) 
            Asm = absorbance of sample 
            Astd = absorbance of standard 
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CHAPTER THREE 
RESULTS 
 
The application of the developed method for the different 
formulations is to study the selectivity of the method and the 
interference of different excipients used in these formulations. 
The results of analysis of these formulations were compared and 
validated with the official BP method. 
Comparisons were made with regard to developing and adopting 
the proposed method on bases of speed, simplicity, sensitivity, 
selectivity, accuracy, precision, reproducibility, cost and ability to 
be employed in routine analysis of the drug.  
Statistical analysis for the results was done to study the accuracy, 
precision, repeatability and reproducibility of the developed 
method. 
3. Results of analysis of NAC 
3.1 Effects of some solvents on the color formation and 
intensity of the reaction product: To see the effect of different 
solvents on the reaction product a sample of standard NAC was 
prepared and processed, the corresponding ABS and λ MAX 
values was recorded and tabulated in table 9.   
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3.1.1 DMSO with acetate  
Table (9): DMSO with acetate done for NAC 150 µg/ml (6, 12, 
24, 30 µg/ml).  
Volume 
in ml 
Concentration  
µg/ml 
λMax ABS 
1 6 µg /ml 450.8 0.134 
2 12 446.7 0.233 
3 18 443 0.385 
4 24 442.2 0.564 
5 30 442.9 0.697 
 
Then volume 1, 5 ml (6, 30 µg/ml) were repeated after 2 hours to 
see their stability.    
Table (10): DMSO with acetate, stability  
 
Vol. Concentration  
µg/ml 
λMax ABS 
1 6 472.5 0.165 
5 30 445.1 0.759 
  
From these tables it is obvious that Solutions are unstable. 
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3.1.2 DMSO without Acetate:  
the reaction was done using DMSO as a solvent but without 
adding acetate to adjust the pH, the results were listed in table 11 
Table (11): DMSO without Acetate 
Vol. Concentration  
µg/ml 
λmax ABS 
3 ml 30 424.9 0.400 
3 ml 30 423.1 0.436 
 
3.1.3 Effect of some solvents on the color formation and 
(intensity of the reaction product). (NAC_DCQ complex) 
 
Table (12): Effect of some solvents on the color formation and  
Intensity of the reaction product. 
  
From this table we notice that absolute ethanol is our right choice 
as a solvent for the reaction to proceed. 
Solvents. Color ABS λmax Dielectric 
constant 
BLK 
color 
Ethanol 
absolute 
Immediate 0.532 438 24.6 Clear 
DMSO Flask turned hot, 
then colored after 
a while  
0.697 450 46.7 Grayish 
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3.1.4 Effect of PH on absorption spectrum of NAC-DCQ 
complex (NAC µg /ml). To see the effect of pH on the 
NAC_DCQ complex 2 (buffer) solutions were used in the 
preparation of NAC (buffered) solution in the PH values 3.5-7. 
3.1.4.1 PH 3.5 
The results observed were summarized in table 13. 
Table (13): Procedure 1, effect of (PH 3.5) on formation, 
intensity and stability of the reaction product (NAC 50 
mg/ml). 
 
PH λ max ABS drug ABS SD Stability 
3.5 438 0.408 0.329 Stable 
3.5 438 0.401 0.355 Stable 
3.5 438 0.406 0.351 Stable 
3.1.4.2 PH 7 
Table (14): Effect of (PH 7) on formation, intensity and 
stability of the reaction products done for 50 µg/ml 
PH λ max ABS Stability Drug SD 
7 438 0.773 0.689 unstable 
7 438 0.748 0.679 unstable 
7 438 0.727 0.673 unstable 
7 438 0.726 0.679 unstable 
7 438 0.721 0.680 unstable 
7 438 0.720 0.669 unstable 
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Table (15): Effect of (PH 7) on blank color, formation, 
intensity and stability of the reaction product, done for 30 
µg/ml 
 
PH λ max Blank Color ABS Stability 
Drug SD 
7 438 Pale pink 0.445 0.486 0 
    0.440 0.431  
7 438 Blank color stable 0.448 0.471 0.5 
   0.452 0.430  
7 438 Blank color stable 0.450 0.425 1 
   0.418 0.435  
7 438 Blank color stable 0.425 0.451 1.5 
   0.422 0.397  
7 438 Blank color stable 0.364 0.376 2 
  Grayish 0.353 0.320  
 
pH 3.5 gave stable NAC_DCQ complex , it had been selected for 
our proposed method . 
3.1.5 Effect of different weights of standard and sample 
on absorption spectrum of n-acetyl-L-cysteine  
 Table (16): Effects of different weights of sample  
Standard 
weight 
Volume Concentration 
µg/ml 
ABS λ max 
0.02 3ml 24 0.268 439 
0.025 3ml 30 0.385 438 
0.035 3ml 42 0.466 438.9 
0.05 3ml 60 0.584 438.2 
0.075 3ml 90 0.821 437.5 
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From the above table, 0.025 g of the SD NAC was the suitable 
starting weight for the reaction. 
Table (17): Stability of solutions prepared using different 
weights of sample:  
 Volume Start 1 hour 2 hour 
Abs λ max ABS λ max ABS λ max
A 0.02  3ml 0.268 439 0.285 440.9 0.305 442.8 
B 0.025 3ml 0.385 438 0.385 438 0.380 438 
C 0.035 3ml 0.446 438.9 0.506 440.7 0.511 442.5 
D 0.05  3ml 0.584 438.3 0.630 440.2 0.639 441.7 
E0.075 3ml 0.821 437.5 0.864 438.4 0.852 439.1 
 Table (18) Effects of different weights of standard (freshly 
prepared standard and acetate)  
 
Volume Start 1 hour 2 hour 
Abs λ max ABS λ max ABS λ max 
0.02 3ml 0.25- 
0.287 
438.6-
439.3 
0.275-
0.295 
440.6-
441.1 
0.312-
0.298 
443.3-
441.9 
0.035 3ml 0.463-
0.468 
438.7-
439.0 
0.509-
0.504 
440.6-
440.8 
0.509-
0.514 
442.6-
442 
0.05 3ml 0.587-
0.581 
437.3-
439.1 
0.642-
0.618 
439.2-
441.2 
0.644-
0.634 
440.9-
442.4 
0.075 3ml 0.816-
0.826 
437.5-
437.5 
0.869-
0.859 
438.4-
438.4 
0.854-
0.850 
439 
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3.1.6 Effect of increasing weight of DCQ  
0.035g/10ml instead of 0.025g/10ml  
 
Table (19) effects of increasing weights of DCQ 
 
DCQ Std ABS with  
acetate 
λ max ABS without 
acetate 
λ max
0.035 1ml 0.123 440.2 0.078 409.0 
0.035 3ml   0.318 438.5 0.275 400.5 
0.035 5ml 0.500 438.6 0.448 400.4 
 
Acetate increase intensity 10% and shift wave length to 438nm 
from 400, r values also differed acetate gave r value closer to 1. 
Table (20) comparison between r values: 
 
In using  acetate Without acetate 
R=0.99980 r=0.9929 
B=0.09425 b=0.0925 
A=0.0309 a=0.0105 
 
 
Concentration 
(µg/ml) 
Abs DCQ 0.035g  
with acetate 
ABS  DCQ 0.025g 
 with  acetate 
1ml  0.123 0.121 
3ml  0.318 0.374 
5ml 0.500 0.605 
r 1 = 0.9998 , r 2 = 0.9996 
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We noticed that ABS values with the two weights selected gave 
almost no difference we conclude that no need to increase DCQ 
weight above 0.25%. 
Construction of calibration curve  
3.1.7 Statistics of calibration curves: 
 In the following experiments calibration curves was done   times 
for the SD NAC powder,   times for Solgar 600mg NAC 
vegetable capsules and for parvolex® sample solution. 
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3.1.7.1Calibration curves for standard: 
 
Table (21): Absorbance values for standard NAC calibration 
curve No (1)  
 
 
ABS DCQ Concentration µg/ml Standard 
0.121 1ml 10 1ml 
0.237 1ml 20 2ml 
0.374 1ml 30 3ml 
0.484 1ml 40 4ml 
0.598 1ml 50 5ml 
 
 
 
Figure (14): Standard NAC calibration curve no (1) 
R= 0.99935 
B=0.01201 
A=2.5×10 -3 
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Table (22): Absorbance values for standard NAC calibration 
curve No (2)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.096 1ml 
2ml 20 0.187 1ml 
3ml 30 0.286 1ml 
4 ml  40 0.380 1ml 
     
   
 
Figure (15): Standard NAC calibration curve no (2) 
 
r=0.99988 
b=9.51 x 10-³ 
a= -5 x 10-4  
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Standard NAC curve no (3): 
 Table (23): Absorbance values for standard NAC calibration 
curve No (3)  
  
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 5.08 0.151 1ml 
2ml 10.16 0.247 1ml 
3ml 15.24 0.371 1ml 
4ml  20.32 0.494 1ml 
5ml  25.4 0.600 1ml 
 
 
Figure (16): standard NAC calibration curve 
No (3) 
R=0.9991 
B=0.01145 
A=0.0291 
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Table (24): Absorbance values for standard NAC  
  Calibration curve no (4)  
 
Volume Concentration 
µg/ml 
ABS 
1ml 10 0.121 
2ml 20 0.238 
3ml 30 0.374 
4ml  40 0.484 
5ml  50 0.605 
 
 
 
Figure (17): standard NAC calibration curve No (4) 
R=0.99957 
B=0.01214 
A=2x10-4 
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Table (25): Absorbance values for standard NAC  
  Calibration curve no (5)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 9.8 0.096 1ml 
2ml 19.6 0.187 1ml 
3ml 29.4 0.286 1ml 
4ml 39.2 0.380 1ml 
 
 
 
Figure (18): Calibration curve for standard no (5) 
 
r=0.99988 
b=0.00970 (b=9.70x10-3) 
a= -5×10-4  
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Table (26): Absorbance values for standard NAC  
  Calibration curve no (6)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.151 1ml 
2ml 20 0.247 1ml 
3ml 30 0.371 1ml 
4ml 40 0.494 1ml 
5ml  50 0.600 1ml 
 
 
 
 
 
Figure (19): standard NAC calibration curve no (6) 
R=0. 9991 
B=0.01145 
A=0.0291 
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Table (27): Absorbance values for standard NAC  
  Calibration curve no (7)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.121 1ml 
2ml 20 0.238 1ml 
3ml 30 0.374 1ml 
4ml 40 0.484 1ml 
5ml  50 0.605 1ml 
 
        
Figure (20): standard NAC calibration curve no (7) 
r=0.99957  
b=0.01214 
a=2x10-4  
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3.1.7.2 Application of the proposed method to a dosage form : 
3.1.7.2.1 NAC 600 mg vegetable capsules made by Solgar 
3.1.72.2 parvolex ® injection 
3.1.7.2.1 Calibration curves for NAC 600 mg vegetable 
capsules made by Solgar: 
Table (28): Absorbance values for Capsules calibration curve 
no (1)  
Volume Concentration 
µg/ml 
Abs DCQ volume 
1ml 10 0.157 1ml  
2ml 20 0.298 1ml 
3ml 30 0.470 1ml 
4 ml  40 0.611 1ml 
5 ml  50 0.776 1ml  
 
R=0.9995  
b=0.01551 
 
Figure (21): NAC 600 mg vegetable capsules calibration  
curve no (1) 
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Table (29): Absorbance values for NAC 600 mg vegetable 
Capsules calibration curve no (2)  
 
Volume Concentration 
µg/ml 
Abs DCQ volume 
1ml 10 0.148 1ml  
2ml 20 0. 286 1ml 
3ml 30 0.440 1ml 
4 ml  40 0.562 1ml 
5 ml  50 0.70 1ml  
 
 
Concentration (µg/ml)
5040302010
A
B
S
0.700
0.600
0.500
0.400
0.300
0.200
0.100
R Sq Linear = 0.999
 
Figure (22): NAC 600 mg vegetable capsules calibration  
curve no (2) 
R=0.9956 
B=0.01127 
A=0.02919 
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Table (30): Absorbance values for NAC 600 mg vegetable 
Capsules calibration curve no (3)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.159 1ml 
2ml 20 0.316 1ml 
3ml 30 0.476 1ml 
4 ml  40 0.635 1ml 
5 ml  50 0.794 1ml 
     
 
Figure (23): NAC capsules calibration curve no (3) 
r = 0.99999 
b = 0.01589 
a = -7×10-4  
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Table (31): Absorbance values for NAC 600 mg vegetable 
Capsules calibration curve no (4)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.157 1ml 
2ml 20 0.276 1ml 
3ml 30 0.378 1ml 
4ml 40 0.479 1ml 
5ml  50 0.574 1ml 
 
 
Figure (24): NAC capsule calibration curve no (4) 
R=0.9991 
b=0.01039 
a=0.0613 
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Table (32): Absorbance values for NAC 600 mg vegetable 
Capsules calibration curve no (5)  
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.148 1ml 
2ml 20 0.293 1ml 
3ml 30 0.440 1ml 
4ml 40 0.589 1ml 
5ml  50 0.739 1ml 
 
 
Figure (25): NAC 600 mg vegetable capsules calibration  
curve no (5) 
R=0.99997 
B=0.01478           
A= -1.6 x 10-³  
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Table (33): Absorbance values for NAC 600 mg vegetable 
capsules calibration curve no (6) 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.159 1ml 
2ml 20 0.316 1ml 
3ml 30 0.475 1ml 
4ml 40 0.634 1ml 
5ml  50 0.793 1ml 
 
 
Figure (26): NAC 600 mg vegetable capsules calibration  
curve no (6) 
r = 0.99999 
b =   0.01586 
a = -4 ×10-4  
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3.1.7.2.2  Parvolex ® injection calibration curves: 
Parvolex ® injection calibration curve no (1)  
Table (34) Acetylcysteine parvolex ® sample solution    
(Concentration 10 mg/ 100ml; 0.1mg/1ml (100 µg /ml)) 
 
Volume Concentration 
µg/ml
ABS 
1ml 10 0.0484 
2ml 20 0.0948 
3ml 30 0.1496 
4 ml  40 0.1936 
5 ml  50 0.2392 
 
 
Concentration(µg/ml)
50.0040.0030.0020.0010.00
A
B
S
0.250
0.200
0.150
0.100
0.050
0.000
R Sq Linear = 0.999
 
Figure (27): Acetylcystiene parvolex ® 100 µg/ml 
Injection calibration curve no (1) 
R=0.9993 
B=0.004804 
A= 1×10-3  
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3.1.7.3 Average ABS values: 
Table (35): Average ABS values no (1) 
 
Volume Concentration 
µg/ml 
Abs DCQ volume 
1ml 10 0.152 1ml  
2ml 20 0.273 1ml 
3ml 30 0.385 1ml 
4 ml  40 0.47766 1ml 
5 ml  50 0.567 1ml  
 
 
 
 
Figure (28): Average ABS values for standard NAC  
curve no (1) 
r=0.9976 
b=0.010 
a=0.060 
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Table (36): Average ABS values no (2)    
 
Volume Concentration 
µg/ml 
ABS 
1ml 10 0.179 
2ml 20 0.357 
3ml 30 0.533 
4 ml  40 0.711 
5 ml  50 0.890 
 
 
 
 
Figure (29): Average ABS values for standard NAC  
curve no (2) 
                R=0.99999 
                B=0.01776 
                A=1.2 x 10-³  
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Table (37): Average ABS values (3)  
 
 
Volume Concentration 
µg/ml 
ABS DCQ 
1ml 10 0.156 1ml 
2ml 20 0.310 1ml 
3ml 30 0.466 1ml 
4ml 40 0.622 1ml 
5ml  50 0.778 1ml 
 
 
 
 
Figure (30): Average ABS values for standard NAC  
curve no (3) 
R=0.99999 
B=0.0155 
A= - 4 
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3.1.7.4 Comparison between absorbance values obtained by 
standard and sample: 
Table (38): standard and sample ABS values no (1)  
ABS 
sample 
ABS 
standard 
DCQ 
Concentration 
µg/ml 
volume 
0.169 0.161 1 10 1ml 
0.478 0.482 1 30 3ml 
0.798 0.800 1 50 5ml 
 
R1= 0.9999                                      R2=0.9999 
A1=2.083×10 -3                                A1=9.917×10 -3  
B1= 0.015975                                  B2= 0.015725  
B1/ b2 = 101.58% 
  
 
Figure (31) Comparison between standard and sample 
calibration curves no (1) 
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Also the following formula was adopted to calculate content of 
NAC , as w/w %of capsules : 
Slope sample curve/ Slope std curve ×100% 
102.87±1.82, n = 2. 
 
Table (39) standard and sample ABS values no (2) 
ABS 
sample 
ABS 
standard DCQ 
Concentration 
µg/ml volume 
0.159 0.126 1 10 1ml 
0.296 0.272 1 30 3ml 
0.423 0.401 1 50 5ml 
 
R1=0.9993                                        R2=0.9997  
B1=6.875×10– 3                                 B2=6.6×10– 3            
A1=0.0600                                        A2=0.0947 
  B1/ B2 = 6.875×10– 3 ÷ 6.6×10– 3 ×100 = 104.16%                              
 
 
Figure (32): Comparison between standard and sample 
calibration curves no (2)  
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3.1.7.5 Calculation of the limit of detection: 
Table (40) Values for   
Calculation of the limit of detection: 
 
Χi Υi   Χi-Χ (Χ-Χ)² Υi-  Ÿ (Υi-  Ÿ)² (Χi-Χ)(Υi-  Ÿ) 
10 0.153 -20 400 -0.2761 0.0762 5.522 
20 0.2945 -10 100 -0.1346 0.01811 1.346 
30 0.446 0 0 0.0169 0.00028561 ZERO 
40 0.530 10 100 0.1009 0.01018081 1.009 
50 0.722 20 400 0.2929 0.085790 5.858 
150 2.1455 Zero 1000 Zero 0.191194 13.735 
 
R = 0.9998 
Yв = A =0.0121 
B = 0.014235 
L.O.D = 0.769  
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3.1.7.6 Molar ratio  
 NO of DCQ moles = 1.568x10-4 M.  
3.1.7.6.1 Fixed DCQ concentration  
Table (41): Fixed DCQ concentration  
 
Std M DCQ M ABS Conc. ratio
0.5 3.06x10-5 2.5 1.55x10-4 0.085 0.197 
1 6.12x10-5 2.5 1.55x10-4 0.166 0.394 
1.5 9.19x10-5 2.5 1.55x10-4 0.262 0.592 
2 1.22x10-4 2.5 1.55x10-4 0.330 0.787 
2.5 1.53x10-4 2.5 1.55x10-4 0.410 0.987 
3 1.83x10-4 2.5 1.55x10-4 0.402 1.180 
3.5 2.14x10-4 2.5 1.55x10-4 0.400 1.38 
4 2.45x10-4 2.5 1.55x10-4 0.396 1.580 
4.5 2.75x10-4 2.5 1.55x10-4 0.393 1.77 
5 3.06x10-4 2.5 1.55x10-4 0.400 1.97 
 
Concentration ratio
2.0001.5001.0000.5000.000
AB
S
0.400
0.300
0.200
0.100
Footnote  
Figure (33): Molar ratio curve fixed DCQ concentration 
R=0.998 
B=0.1628 
A=6.4X10-3 
(Supposed) DCQ= 0.0161g/50ml 
M=1.5300 mole/L NAC= 0.0125g/50 
M=1.5319mole/L 
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3.1.7.6.2 Fixed standard NAC concentration 
Table (42) fixed standard concentration  
No of standard NAC moles = 1.53×10-4  
 
Standard 
(0.0143g) 
M  DCQ M ABS Conc. 
ratio 
2..5 1..53 × 10-4 0.5 4×10-5 0.047 3.825 
2..5 1..53 × 10-4 1 8.08×10-5 0.084 1.893 
2..5 1..53 ×10-4 1.5 12.1×10-5 0.190 1.264 
2..5 1..53 ×10-4 2 16.17×10-5 0.220 0.946 
2..5 1..53 × 10-4 2.5 20.22×10-5 0.258 0.756 
2..5 1..53 × 10-4 3 24.2×10-5 0.255 0.632 
2..5 1..53 × 10-4 3.5 28.3×10-5 0.250 0.540 
2..5 1..53 × 10-4 4 32.3×10-5 0.252 0.474 
2..5 1..53 × 10-4 4.5 36.3×10-5 0.250 0.421 
2..5 1..53 × 10-4 5 40.0×10-5 0.249 0.382 
 
Conentration ratio
4.0003.0002.0001.0000.000
A
B
S
0.300
0.250
0.200
0.150
0.100
0.050
0.000
 
Figure (34): Molar ratio curve fixed standard concentration 
Two methods to find out the reaction ratios are 1:1 equimolar 
ratio:  
(1) From figure  
B1=B2 
(2) r= 0.99005   r= 0.991 
  B=0.1604           b=0.1602 
  A=0.0512    a=0.0381 
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3.1.8 Titremetric method:  
Each ml of 0.05M iodine VS is equivalent to 16.23mg of 
Acetylcysteine  
→+−−−−−
KI
ISHCHCNHCCH
ICOOHII 22 23
2
 
Volume of 0.049 M iodine was found to be 12.6 ml. 
3.1.9 Added recovery 
Table (43):  added recovery  
2ml sample 2ml standard Mixture 
0.220 0.220 0.444 
0.225 0.220 0.447 
0.220 0.210 0.441 
0.227 0.220 0.449 
0.225 0.223 0.448 
0.223 0.221 0.446 
 
3.1.10 Interfering amino acids: 
Reaction of DCQ with each of L- cysteine, L-phenylalanine and 
L- tyrosine is negligible.  
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3.2 Part B: Results for ACA 
Ascorbic acid has been frequently used as analytical reagent in 
analytical chemistry .It’s reported to have a selective reaction 
with ammonia, primary aliphatic amines of type R-CH2-NH2 
(λ max 390 and 532 nm), amino acids with α-aminoacyl function 
λ max about 400 nm , on the bases of these reports a simple 
method is developed for the amino acid analogue ACA analysis .  
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3.2.1 Different factors affecting ACA –Ascorbic acid complex 
3.2.1.1 Boiling time   
Table (44) Estimation of ACA-ascorbic acid complex reaction 
time and stability at peak (1) 530 nm: 
  
Conc. 
µg/ml. 20min 30min 40min 
4 0.059 0.08 0.078 
8 0.149 0.162 0.15 
12 0.22 0.241 0.232 
16 0.259 0.329 0.322 
Correlation 
coefficient 
r=0.98658`r=0.9997 
r=0.9987 
 
 
15.00012.50010.0007.5005.000
0.350
0.300
0.250
0.200
0.150
0.100
0.050
 40min 
 
 30min 
 20min 
 
 40min 
 
 30min 
 20min 
 
 R Sq Linear = 0.972
  R Sq Linear = 1
 R Sq Linear = 0.998
 
 
Figure (35): Effect of boiling time (10, 20, 30, and 40 min) on 
stability and reaction time of ACA-ascorbic acid complex at 
peak 530 nm 
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Table (45) Estimation of ACA-ascorbic acid complex reaction 
time and stability at peak (2) 390 nm: 
 
Conc. 
µg/ml. 20min 30min 40min 
4 0.167 0.245 0.235 
8 0.418 0.491 0.435 
12 0.642 0.725 0.661 
16 0.753 0.99 0.931 
 r=0.9868r=0.9997 r=0.9976 
 
 
15.00012.50010.0007.5005.000
1.000
0.800
0.600
0.400
0.200
0.000
 40min 
 30min 
 20min 
 
 40min 
 30min 
 20min 
 
 R Sq Linear = 0.974
  R Sq Linear = 0.999
 R Sq Linear = 0.995
 
 
Figure (36) Effect of boiling time (10, 20, 30, and 40 min) on 
stability and reaction time of ACA-ascorbic acid complex at 
peak 390 nm 
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3.2.2 Stability of ACA-ascorbic acid complex after 16 hours 
 
Table (46): Stability of ACA-ascorbic acid complex after 16 
hours at peak (1) 530 nm  
 
Conc. 
µg/ml. 1hour 16 hour 
4 0.076 0.074 
12 0.257 0.257 
20 0.413 0.418 
 r=0.9990r=0.9993 
 
 
20.00015.00010.0005.0000.000
0.40
0.30
0.20
0.10
 16hour 
 1hour 
 
 16hour 
 1hour 
 
 R Sq Linear = 0.998
 R Sq Linear = 0.999
 
Figure (37) Stability of ACA-ascorbic acid complex after 16 
hours at peak (1) 530 nm 
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Table (47): Stability of ACA-ascorbic acid complex after 16 
hours at peak (2) 390 nm 
Conc. 
µg/ml. 1hour 16 hour 
4 0.226 0.224 
12 0.744 0.754 
20 1.204 1.203 
 r=0.9994r=0.9990 
 
20.00015.00010.0005.0000.000
1.25
1.00
0.75
0.50
0.25
 16hour 
 
 1hour 
 16hour 
 
 1hour 
 R Sq Linear = 0.999
 R Sq Linear = 0.998
 
 
Figure (38): Stability of ACA-ascorbic acid complex after 16 
hours at peak (1) 530 nm 
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3.2.1.2Effect of different solvents on color formation and 
intensity of the reaction product ( ACA 12 µg/ml ) 
Table (48)  
Solvent Dielectric 
constant 
Absorbance λMax Stability  color 
DMF 36.7 0.079 530.2 unstable yellow 
DMSO 46.7 0.251 530 stable purple 
 
 
3.2.3 Calibration curves for standard ACA: 
 
 Table (49): Absorbance values for standard ACA calibration 
curve No (1) at 530 nm 
 
ABS Concentration µg/ml 
0.074 4 
0.150 8 
0.220 12 
0.294 16 
0.368 20 
 
  
Figure (39): Calibration curve for standard ACA no (1): at 
530 nm 
r=0.99994 
b=0.0183 
a=1.6×10 -3 
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Table (50): Absorbance values for standard ACA calibration 
curve No (1) at 390 nm  
 
ABS 
Concentration 
µg/ml 
0.226 4 
0.442 8 
0.659 12 
0.882 16 
1.102 20 
 
 
 
Figure (40) Calibration curve for standard ACA no (1): at 
390nm 
 
r=0.99998 
b=0.0548 
a=4.6×10-3 
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Table (51): Absorbance values for standard ACA calibration 
curve No (2) at 530 nm 
 
ABS 
Concentration 
µg/ml 
0.076 4 
0.154 8 
0.226 12 
0.303 16 
0.379 20 
 
 
Figure (41): Calibration curve for standard ACA no (2): at 
530 nm 
 
r=0.99994 
b=0.0188 
a=1.1×10-3  
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Table (52): Absorbance values for standard ACA calibration 
curve No (2) at 390 nm 
 
ABS Concentration µg/ml 
0.226 4 
0.466 8 
0.682 12 
0.906 16 
1.139 20 
 
 
Figure (42): Calibration curve for standard ACA no (2): at 
390 nm 
 
r=0.9998 
b=0.05665 
a=4×10-3 
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Table (53): Absorbance values for standard ACA calibration 
curve No (3) at 530 nm 
 
ABS 
Concentration 
µg/ml 
0.084 4 
0.168 8 
0.246 12 
0.332 16 
0.415 20 
r=0.99990 
b=0.020 
a=1.2×10-3 
 
 
  
Figure (43): Calibration curve for standard ACA no (3): at 
530 nm 
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 Table (54): Absorbance values for standard ACA calibration 
curve No (3) at 390 nm 
 
ABS 
Concentration 
µg/ml 
0.250 4 
0.496 8 
0.722 12 
0.994 16 
1.24 20 
r=0.9996 
b=0.061 
a= -3×10-3 
 
 
 
Figure (44): Calibration curve for standard ACA no (3): at 
390 nm 
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Table (55): Absorbance values for standard ACA calibration 
curve No (4) at 530 nm  
 
ABS 
Concentration 
µg/ml 
0.079 4 
0.16 8 
0.24 12 
0.318 16 
0.400 20 
 
 
 
 
Figure (45): Calibration curve for standard ACA no (4): at 
530nm 
 
r=0.99997 
b=0.02 
a= -6×10-4 
106 
Table (56): Absorbance values for standard ACA calibration 
curve No (4) at 390 nm 
 
ABS 
Concentration 
µg/ml 
0.239 4 
0.482 8 
0.722 12 
0.956 16 
1.202 20 
 
  
 
Figure (46): Calibration curve for standard ACA no (4): at 
390nm 
 
r=0.99997 
b=0.06 
a=2×10-4 
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Table (57): Absorbance values for standard ACA calibration 
curve No (5) at 530 nm  
 
ABS 
Concentration 
µg/ml 
0.078 4 
0.155 8 
0.232 12 
0.310 16 
0.378 20 
 
 
  
Figure (47): Calibration curve for standard ACA no (5): at 
530nm 
r=0.9997 
b=0.0188 
a=4.1×10-3 
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Table (58): Absorbance values for standard ACA calibration 
curve No (5) at 390 nm 
 
ABS 
Concentration 
µg/ml 
0.245 4 
0.465 8 
0.696 12 
0.930 16 
1.134 20 
 
 
Figure (48): Calibration curve for standard ACA no (5): at 
390nm 
r=0.9997 
b=0.0560 
a= 0.0211 
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  Table (59): Absorbance values for standard ACA calibration 
curve No (6) at 530 nm  
 
ABS Concentration µg/ml 
0.08 4 
0.162 8 
0.241 12 
0.329 16 
0.403 20 
 
Concentration (µg/ml)
20151050
A
B
S
0.400
0.300
0.200
0.100 R Sq Linear = 0.999
 
Figure (49): Calibration curve for standard ACA no (6): at 
530nm 
r=0.9997 
b=0.0203 
a= -9×10-4 
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Table (60): Absorbance values for standard ACA calibration 
curve No (6) at 390 nm 
 
ABS 
Concentration 
µg/ml 
0.242 4 
0.491 8 
0.725 12 
0.990 16 
1.212 20 
 
Concentration (µg/ml)
20151050
A
B
S
1.250
1.000
0.750
0.500
0.250
R Sq Linear = 0.999
 
Figure (50): Calibration curve for standard ACA no (6): at 
390nm 
 
r=0.9997 
b=0.060 
a=3×10-4    
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3.2.4 Application of the proposed method to a dosage form: 
Aminocaproic acid injection (250 mg/20 ml)  
 
(5mg/20ml) made by American Reagent Inc. 
 
Table (61): Absorbance values for Aminocaproic acid 
injection made by American Reagent Inc. at 530 nm 
 
ABS Concentration µg/ml 
0.103 4 
0.198 8 
0.310 12 
0.412 16 
0.513 20 
 
Concentration (µg/ml)
20151050
A
B
S
0.600
0.500
0.400
0.300
0.200
0.100
R Sq Linear = 1
 
Figure (51): Calibration curve for sample ACA no (1): at 
530nm 
 r=0.9997 
b=0.025 
a= -3×10-3  
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Table (62): Absorbance values for Aminocaproic acid 
injection made by American Reagent Inc. at 390 nm 
 
 
ABS Concentration µg/ml 
0.314 4 
0.585 8 
0.928 12 
1.234 16 
1.537 20 
 
 
Concentration (µg/ml)
20151050
A
B
S
1.500
1.250
1.000
0.750
0.500
0.250
R Sq Linear = 0.999
 
Figure (52): Calibration curve for sample ACA no (1): at 
390nm 
 
r=0.99952 
b=0.0773 
a= -8.9×10-3 
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Table (63): Spectral data for the reaction of ACA with 
ascorbic acid: 
 
λmax 
(nm) 
Linearity 
range 
(µg/ml)      
Limit of 
detection 
(µg/ml)         
Intercept Slope Correlation 
coefficient 
Molar 
absorptivity 
(Lmol-1 cm-1 ) 
530 4-20 0.287 1.48×10-3 0.01934 0.99985 2492.6 
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3.2.5 Molar ratio: 
Trials were done for different ascorbic acid and ACA 
concentrations, the ratio was found to be 4: 1. 
3.2.5.1A: Trial no (1): ACA conc. = 0.0498 M 
                           Ascorbic acid = 0.099 M  
Table (64) Molar ratio trial no (1): at 530 nm  
 
ACA 
Volume 
concentration  
M ABS 
Vitamin C 
M 
Concentration 
ratio 
ACA/Vit.C 
5 2.492×10-7 0.085 4.985×10-6 0.04998 
10 4.985×10-7 0.166 4.985×10-6 0.10 
15 7.478×10-7 0.166 4.985×10-6 0.150 
20 9.971×10-7 0.167 4.985×10-6 0.20 
25 1.246×10-6 0.089 4.985×10-6 0.2499 
30 1.495×10-6 0.08 4.985×10-6 0.2998 
40 1.994×10-6 0.057 4.985×10-6 0.40 
50 2.492×10-6 0.065 4.985×10-6 0.4998 
 
Concentration ration
0.5000.4000.3000.2000.1000.000
AB
S
0.180
0.160
0.140
0.120
0.100
0.080
0.060
 
Figure (53) Molar ratio trial no (1): at 530 nm 
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Table (65) Molar ratio trial no (2): at 390 nm 
 
ACA 
Volume 
concentration 
M ABS 
Vitamin C 
M 
Concentration 
ratio 
ACA/Vit.C 
5 2.492×10-7  0.29 4.985×10-6 0.04998 
10 4.985×10-7 0.518 4.985×10-6 0.10 
15 7.478×10-7 0.528 4.985×10-6 0.150 
20 9.971×10-7 0.539 4.985×10-6 0.20 
25 1.246×10-6  0.344 4.985×10-6 0.2499 
30 1.495×10-6 0.317 4.985×10-6 0.2998 
40 1.994×10-6 0.260 4.985×10-6 0.40 
50 2.492×10-6 0.265 4.985×10-6 0.4998 
 
Concentration ratio
0.50000.40000.30000.20000.10000.0000
A
B
S
0.5500
0.5000
0.4500
0.4000
0.3500
0.3000
0.2500
 
Figure (54) Molar ratio trial no (2): at 390 nm 
 
 
116 
 3.2.5.2 A: Trial no (2): ACA conc. = 0.02485 M 
                           Ascorbic acid = 0.0997 M  
Table (66) Molar ratio trial no (2): at 530 nm  
 
ACA 
Volume concentration M ABS Vitamin C M 
Concentration 
ratio 
ACA/Vit.C 
10 2.48×10-7 0.073 4.985×10-6 0.0497 
20 4.970×10-7 0.089 4.985×10-6 0.0996 
30 7.455×10-7 0.120 4.985×10-6 0.1495 
40 9.940×10-7 0.139 4.985×10-6 0.1993 
50 1.242×10-6 0.105 4.985×10-6 0.2491 
60 1.491×10-6 0.077 4.985×10-6 0.2990 
70 1.739×10-6 0.047 4.985×10-6 0.3488 
100 2.485×10-6 0.026 4.985×10-6 0.4984 
 
Concentration ratio
0.50000.40000.30000.20000.10000.0000
A
B
S
0.1250
0.1000
0.0750
0.0500
0.0250
 
 
Figure (55) Molar ratio trial no (2): at 390 nm 
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Table (67) Molar ratio trial no (2): at 390 nm 
 
ACA 
Volume 
concentration 
M ABS 
Vitamin C 
M 
Concentration 
ratio 
ACA/Vit.C 
10 2.48×10-7 0.206 4.985×10-6 0.0497 
20 4.970×10-7 0.271 4.985×10-6 0.0996 
30 7.455×10-7 0.386 4.985×10-6 0.1495 
40 9.940×10-7 0.425 4.985×10-6 0.1993 
50 1.242×10-6 0.338 4.985×10-6 0.2491 
60 1.491×10-6 0.301 4.985×10-6 0.2990 
70 1.739×10-6 0.217 4.985×10-6 0.3488 
100 2.485×10-6 0.115 4.985×10-6 0.4984 
 
Concentration ratio
0.50000.40000.30000.20000.10000.0000
A
B
S
0.5000
0.4000
0.3000
0.2000
0.1000
 
Figure (56) Molar ratio trial no (2): at 390 nm 
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3.2.6 Table (68): Added recovery at 530 nm 
 
Standard 4 
µg/ml 
Sample 4 
µg/ml 
% Mixture8 
µg/ml 
0.182 0.167 109.7 0.383 
0.153 0.188 108.2 0.369 
0.152 0.155 106.8 0.328 
 
(X--- =108.23±1.45, n = 3) 
Table (69): Added recovery at 390 nm 
 
Standard 4 
µg/ml  
Sample 4 µg/ml Mixture8 µg/ml  
0.539 0.499 1.108 
0.453 0.558 1.069 
0.452 0.461 1.122 
  0.957 
 
 
Table (70): Added recovery  
 
Standard 2 
µg/ml 
Sample 2 
µg/ml 
Mixture 4 
µg/ml 
0.147 0.172 0.312 
0.140 0.163 0.310 
0.141 0.158 0.332 
  0.339 
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3.2.7 Table (71): Effect of different concentration of vitamin C 
on absorption spectrum of ACA at (530 nm) 
  
ACA Vitamin C ABS  
20 µg/ml 0.005 0.260 
20 µg/ml 0.01 0.444 
20 µg/ml 0.015 0.454 
20 µg/ml 0.02 0.489 
 
Table (72): Effect of different concentration of vitamin C on 
absorption spectrum of ACA at (390nm) 
ACA Vitamin C ABS  
20 µg/ml 0.005 0.795 
20 µg/ml 0.01 1.280 
20 µg/ml 0.015 1.287 
20 µg/ml 0.02 1.404 
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3.2.8 Blank signal against water    
 
Figure (57): Blank signal against water 
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CHAPTER FOUR 
DISCUSSION 
 
Part A: Discussion for NAC  
 
Organic compounds and drugs have been used extensively in 
numerous fields. It can be stated that they will remain of great 
value in future, in spite of the steadily growing resort to purely 
physical methods. The later often necessitate very sophisticated 
and expensive instrumentation .Routine colorimetric analysis can 
be performed with very simple instrumentation, resulting 
nevertheless in sensitive and accurate measurements with the 
advantages of less cost, higher speed and simplicity (Pesez M. 
and Bartos., 1974). 
Most of the reported analysis methods of NAC are time 
consuming, lack selectivity, require sophisticated equipment or 
not simple for routine analysis as example iodomery and HPLC 
methods. 
Therefore the need for a fast, sensitive, simple and selective 
method is obvious, especially for routine quality control analysis 
of pharmaceutical products containing NAC. Due to the lack of 
chromophore and/or auxochrome in NAC molecule, direct 
spectrophotometry can not be used for its analysis. 
2, 6-Dichloroquinone-4-chlorimide (DCQ) has numerous 
applications as an analytical reagent. It has been used for the 
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colorimetric determination of some phenolic and thiol containing 
drugs (Pesez M. and Bartos., 1974). 
In the view of the fact that NAC contains a thiol functional group, 
it was deemed useful to develop a colorimetric method using 
DCQ for its daily routine analysis.    
NAC react with DCQ to give a colored complex that is soluble in 
aqueous media. Absorption spectra were recorded over the range 
200-400 nm.The complex gave an absorption peak at 438 nm at a 
detectable absorption reading 0.243 .This was therefore used for 
the analytical determination. 
Under the same conditions NAC does not absorb at this 
wavelength , due to lack of auxochrome or chromophore in its 
structure (figure-1).Since the DCQ has minimal at the wave 
length of the maximum absorbance of the complex , all 
measurements were performed against a reagent blank. 
The different experimental parameters affecting the colour 
development were extensively studied to determine the optimal 
conditions for the assay procedure .All conditions studied were 
optimized at room temperature (25±1). 
The reaction was conducted at different pH values to investigate 
the reaction time, color intensity, and stability. It is known that 
such parameters are affected by pH (Al-majed, 1999).In the pH 
values used (3.5) the color developed immediately .Maximum 
color intensity was obtained using sodium acetate 1% which gave 
pH 3.5, blank was very clear .Using phosphate buffer pH 7 gave 
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colored blank whose color changed after 2 hours. Despite pH 7 
gave higher absorbance values for both sample and SD compared 
to those with pH 3.5, their blank was colored so they were 
excluded, colored blank lead to rather non reproducible results 
due to blank color variations. Addition of 1 ml of sodium acetate 
1% was just before adding the DCQ reagent solution to adjust the 
pH for the reaction to proceed, it was noticed that only fresh 
acetate solutions gave stable results, so Acetate solution should 
always be fresh.  The use of acetate increased the intensity by 
10% and shifts the wave length to 438 from 400; also solutions 
gave higher r values (0.99980) compared to those without acetate 
(0.9929). 
The effect of different solvents namely absolute ethanol and 
DMSO on the color development was also studied .Immediate, 
intense and stable color was obtained with absolute ethanol. 
However, with DMSO the flask turned hot then colored after 
awhile, blank was clear with ethanol but it gained a color with 
DMSO.Also DMSO gave a rise to two or more peaks beside the   
λ Max variations from (423.1 to 472.5) compared to a single 
sharp peak at 438 obtained with ethanol .This will rule out 
possible interferences and provide better selectivity .The solvent 
mixture (medium) for the reaction was a mixture of 50:50 
absolute ethanol and distilled water.  
The optimal volume and concentration for the DCQ reagent 
required was found to be 1.0 ml of 0.25% w/v in absolute ethanol. 
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Increasing the DCQ reagent concentration from 0.25% to 0.35% 
gave no significant difference almost the same results, so to save 
the DCQ powder from wasting we choose 0.25% suits the 
reaction, it should always be freshly prepared (Table 17). 
The sequence of addition of the reagents as described in the 
method was found to be essential for good reproducibility .Under 
these conditions the color of the complex was immediately 
formed and was stable for more than 2 hours (table 17).The 
results were confirmed by means of monitoring 30 µg/ml SD 
NAC absorbance over 120 minutes period (table 18) (n=5) the 
results mean was 0.3838 with low SD = 2.16×10 to the power -3, 
and RSD (%) = 0.56, which indicates that the complex was stable 
over at least the period specified . 
The validity of the method was tested by analyzing samples of 
NAC. Under the optimum experimental conditions employed 
above, Beerś law was found to be valid over the concentration 
range [6.1 x 10-5 M – 3.05 x 10 -4 M]. The molar absorptivity (ε) 
of the complex was 2130.96 L mole -1 cm -1.This value, being 
relatively high confirms the sensitivity of the method. The 
relationship between the absorbance, A, at 438 nm and 
concentration, C, in morality (M) (the regression equation) was:  
A = 0.0121 + 0.0142 C with a relation coefficient (R²) of 0.999  
(n = 5) indicating good linearity. 
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The detection limit of the studied drug was 0.769 µg/ml; which 
represents the minimum absorbance value that can be measured 
for the color produced by the complex formed. 
The precision of the method was determined on three different 
concentrations of NAC .The results presented in table 40 showed 
a low (SD) varying from 3.055x10-³  to 1x10-³ with relative 
standard deviation varying (RSD %) from 2.47 to 1.66 % for 
NAC concentrations in the range 6.19x10-5 to 3.06x10-4 M. This 
reflects that the method is satisfactory reproducible. 
To study the stoichiometry of the reaction, the molar ratio of 
DCQ to NAC was determined in the reaction mixture by the 
molar ratio method using 1.57x10-4 M for both DCQ and NAC. 
The method was done by fixing DCQ concentration and changing 
NAC concentration over the concentration range specified   
(Table 40), and alternatively by fixing NAC concentration and 
changing DCQ concentration (Table 41). The curves obtained by 
the molar ratio method showed a break point at 0.99 and 0.98 
respectively (figure- 43 and 44) which mathematically represents 
a molar ratio of DCQ: NAC to be 1:1. The results were confirmed 
by means of calculating the b values 0.1604 and 0.1602 
respectively that indicates the formation of 1:1 NAC: DCQ 
complex, indicating that one molecule of NAC denses with one 
molecule of DCQ. According to karmer and Gamson, DCQ reacts 
via the chlorine atom f the chlorimide group with thiols to give a 
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yellow to brown color of dichloroquinone sulfenimide e.g. D-
penicillamine (λ max 431 nm ) ( Figure 62  )( Al-Majed,1999). 
 
 
 
       
  
 
 
+                                         = 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (68): Reaction pathway between DCQ and NAC 
 
By analogy to such reactions, it is proposed that reaction of NAC 
with DCQ will take the pathway outlined in Figure 68. 
 
The appreciable value of molar absorbance (21.30 X10² L mole -
1 cm -1) and the stability of the product permit the successful 
application of the proposed method to the determination of NAC 
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either in pure forms or in commercial formulations (parvolex® 
and NAC 600 mg vegetable capsules made by Solgar ). 
When the proposed method was applied to the determination of 
NAC in NAC 600 mg vegetable capsules made by Solgar against 
NAC authentic sample ( table 38- 39) the mean content % w/w 
was found to be : 102.87±1.82, (n = 2), which indicate the 
applicability of the method for the assay of dosage form. 
The method was also applied to Acetylcysteine parvolex ® 
sample solution   (Concentration 10 mg/ 100ml; 0.1mg/1ml (100 
µg /ml)); the content: 4.804×10-3/0.01201 = 0.4 which is equal to 
their ratio: 
100 µg /ml / 250 µg /ml = 0.4 i.e. 100 % w/ v. 
The official method (United States pharmacopoeia 31, 2008) 
recommends the use of an iodometric method. 
Advantages of the proposed method over the BP method: 
 
1. Simple and speed: minimal manipulation steps, 5 minutes 
preparation steps compared to mechanical titration which may 
take half an hour. 
2. Cost effective: cheap DCQ powder, water as solvent and 
ethanol makes the method quietly economic. 
3. Simple instrumentation. 
4. The method is quite good for routine analysis in countries like 
Sudan, where cost of analysis is of great importance. 
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Reaction of DCQ with each of L- cysteine, L-phenylalanine and 
L- tyrosine is almost negligible. Those are derivatives and 
analogues of NAC and may possibly found with NAC 
formulations. 
It is obvious that the method is not affecting by the interfering 
amino acids i.e. they don’t interfere   NAC-DCQ complex 
formed. 
It is thus possible to successfully use the present method for 
determination of NAC content in NAC formulations without prior 
separation or any interference. 
The developed spectrophotometric method which uses DCQ as 
the analytical chromogen is rapid, simple with reproducible 
results.  
The color developed immediately and is long lasting. 
The method is sensitive and economical as the major solvents are 
ethanol and water which are available and cheap, and only small 
quantities of the substance and the reagent are used. 
In conclusion the method can be successfully applied to the 
determination of NAC in bulk and pharmaceutical dosage forms.   
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Part B: Discussion for ACA  
Ascorbic acid has been frequently used as analytical reagent in 
analytical chemistry .It’s reported to have a selective reaction 
with ammonia, primary aliphatic amines of type R-CH2-NH2 
(λ max 390 and 532 nm), amino acids with α-aminoacyl function 
λ max about 400 nm, on the bases of these reports a simple, 
sensitive, and selective method is developed for the amino acid 
analogue ACA determination in bulk and pharmaceutical 
formulations. 
Most of the reported methods for analysis of ACA are time 
consuming, lacking selectivity require sophisticated equipment or 
not simple for routine analysis. 
ACA, like amino acids, contains (R-CH2) directly attached to an 
amino group, it is therefore one of the primary aliphatic amines. 
ACA exhibit weak UV–absorption in the range. Therefore, a 
suitable chromogen is needed to react with ACA to obtain a more 
UV light absorbing chromophore that can be useful for a sensitive 
spectrophotometric determination of ACA in bulk and dosage 
forms. Ascorbic acid is a chromogen known to react with amino 
containing compounds .It was found to react with ACA producing 
a purple colored product absorbing at 530nm and 390nm.  
The different experimental affecting the color development, 
intensity and stability were studied. These factors include solvent, 
the reagent concentration, the reaction time and temperature. 
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The suitable concentration of ascorbic acid for the reaction was 
found 1 ml of 0.1% w/v , as in table (71) it is the only 
concentration that gives high intensity and the peak at 390nm was 
96.09% three times  the peak at 530nm. 
The different solvents used were DMSO; DMF .DMF gave pale 
yellow color and weak absorption bands, table           . 
The effect of boiling time on the product color intensity and 
stability was studied. Table (1 ), (2), (3) shows the different 
results .Boiling to 30 min gave solutions with the highest (0.9997) 
values  and are stable for at least 16 hours ( r = 0.9993) therefore 
fixed 30 min of boiling was the most suitable time ( best r-value 
and color intensity ) and to give more reproducible absorbances 
with low standard deviations. 
The sequence of addition of the reagent as described under 
calibration curve was essential for good reproducibility. The 
formed color was found to be stable for at least 22 hours. The 
optimized conditions were utilized to construct the calibration 
graph using authentic ACA.  
Beerś law was obeyed for ACA concentration 4 – 20 µg/ml 
(3.049 x 10- M----1.52 × 10-4 M). The molar absorptivity (ε) of 
the complex was 2492.6 L mole-1 cm-1.This value, being relatively 
confirms the sensitivity of the method. The relationship between 
the absorbance, A, at 530 nm and concentration, C, in morality 
(M) (the regression equation) was:  
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A = 1.44x10-³ + 0.01934 C with a relation coefficient (R²) of 
0.999 (n = 5) indicating good linearity.  
The detection limit of the studied drug was 0.287µg/ml; which 
represents the minimum absorbance value that can be measured 
for the color produced by the complex formed. Spectral data for 
the reaction of ascorbic acid with ACA are represented in table  
(63).The low values for standard deviation of the slope 
(2.260×10-3 ) and correlation coefficient (1.015×10-4) reflected the 
consistency of the prepared calibration graphs. 
The limit of detection was calculated using the formula: 
 
                          L.O.D = Yв + 3Sв 
 
Where Yв = blank signal  
And      3Sв = Three standard deviations of the blank. 
The accuracy of the procedure and freedom of interference by the 
injection excipients was confirmed by the obtained results for 
recovery testing of added amount of authentic ACA to the 
injection solution in the ratio of 1:1.The results showed good 
recovery for the injection (X =108.23±1.45, n = 3). This, together 
with the good reproducibility reflected the good accuracy and 
precision of the method.  
The method was applied for the drug samples using 
Aminocaproic acid injection (250 mg/20 ml) made by American 
Reagent Inc. The injection being highly concentrated it gave 
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intense absorbance, content w/v% = 125%, for its processing it 
was diluted. 
 
During the study of the effect of different solvents used to prepare 
ascorbic acid solution on the color formation, solutions of 
variable color intensities were obtained. In an attempt to reach 
explanation for this solvent effect on the reaction process, two 
solvents of different dielectric constants (D.E.) were selected. 
Table (48) summarizes the results obtained which reflectedthat 
hyperchromic effect was observed for solvent with higher D.E. 
(DMSO). An assumption was made that DMSO with its medium 
polarity (DE 47) possibly enhance the reactivity of ascorbic acid 
and stabilize the formed Л- Л and n- Л transitions. 
Several trials were done to find out the reaction ratio, equimolar 
concentrations gave peaks at 390 nm that are not three times those 
at 530 nm, or gave peaks that are not at exactly 390 nm e.g. 
(366,486,370 nm), or decreased absorbance by the increased 
concentration. But as we increased ascorbic acid concentration 
and decreased ACA concentration   (ACA conc. = 0.0498, 
Ascorbic acid = 0.099 M) the ratio appears, the reaction was 
found to be 4: 1 (ACA conc. = 0.02485 M, Ascorbic acid = 
0.0997 M), excess of component L ACA in this case causes a 
decrease in absorbance owing to the stepwise formation of higher 
order complexes that have smaller molar absorptivity values at 
this wavelength (Christian, et al., 1978). 
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The official United States pharmacopoeia (USP 23, 2001) method 
recommends use of a high performance liquid chromatography. 
The advantage of the proposed method over the USP method: 
1- Simple and safe time. 
2- Cost effective: cheap ascorbic acid powder, DMSO as 
solvent makes it quietly economic. 
3- Simple instrumentation: U.V. visible spectrophotometer is 
quite enough to conduct the method compared to degasser, 
special filters, injector etc in the USP method. 
The method is quite good for routine analysis in countries like 
Sudan, where accessibility to modern analytical equipment is 
difficult and cost of analysis is of great importance. 
The official method was found to be inapplicable due to the lack 
of laboratory facilities beside absence of reagent required for 
such analysis. 
The above reported method for the determination of ACA in the 
pure form and in pharmaceutical preparation, proved to be simple, 
precise, accurate and economic. The bathochromic shift obtained 
by reacting ACA with ascorbic acid is considered selective for 
primary aliphatic amines. 
The colored product was found to have two wave lengths at 530 
nm and 390 nm. The absorbance ratio between the two 
wavelengths can be used as an identification method since the 
ratio is constant in the concentration range used (4-20 µg/ml). 
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